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ABSTRACT 
 
EMILY ANNA OBLATH: Microfluidic Devices for Performing Multiplexed 
Immunoassays and Nucleic Acid Tests 
(Under the direction of J. Michael Ramsey) 
 
This work describes the development of microfluidic devices to perform 
multiplexed immunoassays and nucleic acid tests for point-of-care (POC) diagnostics.  
Diagnostic testing is usually performed at centralized laboratories, imposing a significant 
delay in treatment.  In contrast, POC testing is performed by the primary healthcare 
provider, and the results can be used to implement proper treatment immediately.  Saliva 
can be an ideal sample for POC diagnostics since it is easily collected and contains many 
disease biomarkers.  This work focuses on using saliva to monitor and diagnose 
pulmonary diseases.  Cytokine biomarkers are measured as early indicators for asthma or 
cystic fibrosis, while DNA is characterized to identify bacteria that can cause respiratory 
infections.   
The first device described uses sandwich immunoassays to measure cytokines.  
The polydimethylsiloxane (PDMS)-glass hybrid chip integrated microfluidic channels 
with a 900-well microarray.  The wells were loaded with antibody-functionalized 
microspheres from a random mixture.  An encoding strategy was used for multiplexed 
assays so that microspheres functionalized with antibodies for one analyte could be 
distinguished from microspheres for another analyte.  Optimization of the assay for 
reduced analysis time and a low limit of detection is described for two cytokines, VEGF 
 iv
and IL-8.  The optimized assay required less than one hour, and the theoretical limits of 
detection were found to be well below physiological levels reported in the literature.   
A second device was developed to integrate DNA extraction and polymerase 
chain reaction (PCR) amplification for the detection of bacteria found in saliva.  Sample 
extraction is a particularly challenging problem for POC, PCR-based diagnostics.  In this 
device, DNA extraction was accomplished by filtering samples through an aluminum 
oxide membrane (AOM) integrated with a PDMS-glass channel structure.  Parallel 
reaction wells located above the AOM were used to perform multiplexed analyses.  
Several designs and detection strategies were explored as the device was optimized.  The 
final format incorporated 7 reaction wells and real-time detection with fluorescent probes 
or an intercalating dye.  Detection of as little as 8-12 copies of purified template DNA 
was achieved.  The successful identification of bacteria and spiked genomic DNA in 
saliva is also described. 
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CHAPTER 1 
INTRODUCTION TO POINT-OF-CARE SALIVARY DIAGNOSTICS 
1.1 Microfluidics and Point-of-care Diagnostics 
Microfluidics concerns the behavior and manipulation of fluids on the micro-
scale.  It can be used as a strategy for taking macro-scale techniques and procedures and 
adapting them onto a device to perform the same actions on the microscale.  Ideally, 
microfluidics would integrate all the steps for a procedure usually performed on the 
bench top into a single device, a micro total analysis system (μTAS) or Lab-on-a-chip 
(LOC).
1-4
  Often that device can take the form of a small chip, something comparable to a 
microscope slide, that contains millimeter- to micrometer-scale fluidic channels and 
features for manipulating and transporting fluids from one region of the chip to another.
3, 
5, 6
  If possible, the chip would provide sample-in answer-out capability, with little or no 
interaction from the user.
1, 3-5, 7-11
  The detection method of the ‘answer’ could be 
integrated as part of the chip or could be housed in a separate instrument.
11, 12
 
The initial motivation for miniaturization with microfluidics was to improve 
performance in applications requiring high resolution separations and sensitive 
detection.
3, 5
  The decreased size of LOC devices also leads to other advantages including 
lower consumption of sample and reagents, lower cost, and shorter analysis times.
3, 5, 11, 12
  
Much of the early research focused on fabricating functional microscale components such 
as pumps, valves, and chemical sensors.
3
  This early work created silicon-based devices 
using microfabrication techniques developed in the semiconductor industry.
3, 5
  Device 
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materials eventually moved towards polymers, such as poly(dimethysiloxane) (PDMS), 
that are more suitable for biological samples, require less complex fabrication procedures 
for components like pumps and valves, and are less expensive.
3, 5, 9
  Further research 
shifted towards integrating multiple steps, such as separation and detection, onto a single 
device.
3, 5, 7, 9
  This led to the potential for automation of analytical techniques with 
extremely easy to use devices, one of the biggest advantages of microfluidics.
1, 5, 11
   
The sample-in answer-out promise of microfluidics makes it extremely well 
suited for point-of-care (POC) diagnostics.  The goal of POC diagnostics is to perform 
analyses at or near where the patient is receiving care.
13, 14
  An ideal test would be fast 
enough for the patient to receive results while waiting in the doctor’s office, emergency 
room, or at home.  Current diagnostic testing typically takes place at centralized labs.
11, 13-
15
  Samples must be collected, sometimes at the point-of-care, sometimes at a separate 
testing site such as a LabCorp or Quest Diagnostics lab, and then packaged and 
transported to the testing facilities for analysis.  Depending on the tests ordered and the 
frequency at which the results are reported, the results may not be available to the care 
providers for many days.
14-16
  It may take even longer for the results to be communicated 
to the patient and for any necessary treatment decisions to be made.  POC testing reduces 
the turn-around time to get results, eliminates sample packaging and transportation costs, 
decreases labor costs, and lowers the chances of contaminated, mislabeled, and lost 
samples.
15, 16
  The fast turn-around time of POC testing can even improve patient 
outcomes, particularly for test results that impact a critical decision in patient care.
15
  An 
automated sample-in answer-out LOC would be ideal for these tests, reducing the time 
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required and need for trained personnel at a centralized laboratory to obtain the 
information necessary to monitor or make treatment decisions.   
1.2 Saliva 
Whole saliva is made up of components from many sources.  It contains 
secretions from the parotid, submandibular, sublingual, and minor salivary glands, 
crevicular fluid from the oral mucosa, as well as bacteria, leukocytes, and sloughed 
epithelial cells.
17
  Each salivary gland contributes different mixtures of proteins to the 
whole saliva.
18
  Saliva serves many purposes important for both oral health and overall 
health.  The continuous flow of saliva washes bacteria and food out of the mouth, and the 
saliva also acts as a buffer, neutralizing acid and protecting tooth enamel.
18
  Saliva also 
begins digesting food as it is eaten, and aids in swallowing the food.
18
  Without saliva, 
teeth would quickly decay and the mouth would be vulnerable to infections.  Individuals 
with chronically dry mouth, such as those with Sjögren’s syndrome, often develop 
serious problems with tooth decay and cavities.
19
  
Saliva contains a huge number of analytes and possible biomarkers that come 
from all of its components, making it a good candidate for diagnostic tests.  Blood and 
urine are two of the most commonly used samples for diagnostic tests.  In some instances 
blood is the only choice, but for many analytes saliva can be used instead.
16, 20
  Most 
analytes found in blood and urine can also be found in saliva, although they are often 
present in lower concentrations.
16, 20, 21
  Many steroid, hormone, drug, and antibody levels 
in saliva have been found to correlate well with those found in blood or urine, although 
this is not true in all cases.
16, 20
  Antibodies to HIV, protein biomarkers for cancer, and 
inflammatory cytokines are just a few of the analytes that have been detected in saliva.
22-
 4 
24
  Levels and types of bacteria in saliva have been linked to periodontal health, bad 
breath, and pancreatic cancer.
25-27
  If analyte levels correlate with those found in other 
samples and lower analyte concentration is not a critical problem, saliva offers many 
advantages over blood samples.  Saliva is easier to obtain with painless, non-invasive 
collection that does not require phlebotomy.  Collecting saliva is less dangerous than 
blood collection for the person doing the collecting, and, with fewer privacy concerns, it 
is easier to maintain a chain of custody for saliva samples than for urine samples.
16, 20
   
There are many ways to collect both whole saliva and saliva from individual 
glands.  The most basic collection method is unstimulated collection of whole saliva 
through draining or drooling.  The patient allows saliva to drain out of their mouth into a 
container with minimal mouth movement.
28
  Evaporation during the collection time can 
be problematic for the draining method, so spitting can be used as an alternative although 
it does have a stimulating effect on the saliva flow.
28
  Chewing on paraffin wax or 
unflavored chewing gum, and introducing citric acid to the mouth have also been used to 
stimulate saliva flow for collection.
28, 29
  Swabs and commercially available absorbent 
pads can also be used for whole saliva collection.
28, 29
  Suction methods can be used to 
collect either whole saliva or secretions from the individual glands, but require more 
training and specialized equipment, and are more invasive for the patient.
28
   
The method used to collect and store saliva for diagnostic testing depends on the 
analytes and biomarkers being targeted, but there are also some general properties of 
saliva that must be considered for all analytes.  The most important consideration is that 
the methods used to collect samples must be consistent for a given test.
17, 29
  This includes 
collecting repeated samples in the same way, collecting samples at the same time of day 
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and under the same environmental conditions, and limiting eating and drinking for a 
period of time, usually 1-2 hours, prior to sample collection.
17, 30, 31
  Flow rates and 
composition of saliva can vary greatly between samples, even for the same individual, so 
saliva may sometimes be better suited for qualitative tests than for quantitative tests.
18, 20, 
29
 
If the target analytes include protein or enzyme biomarkers, care must be taken to 
preserve them until the analysis is performed.  The bacteria and digestive enzymes found 
in saliva have proteolytic activity and will alter the concentrations of proteins in the 
sample if not stopped.
17, 29
  Collecting saliva on ice can slow or stop the degradation of 
proteins in the sample.
17, 29
  The addition of protease inhibitors such as EDTA, 
phenylmethanesulfonylfluoride, soy bean trypsin inhibitor, and E-64 (an epoxide-based 
cysteine protease inhibitor) to the collection vials can also be helpful for slowing protein 
degradation.
29
  Sodium azide can also be added to slow bacterial growth and thus slow 
protein breakdown, but it will interfere in downstream analysis if an enzyme-linked 
immunosorbent assay (ELISA) is used.
29
  The salivary proteins can also be lost from 
adsorbing to the surfaces of the collection device if materials such as glass are present.
17
  
If an absorbent pad or swab is used for saliva collection, the analytes must be compatible 
with the material chosen.  Another consideration is that highly prevalent proteins in saliva 
can sometimes affect or obscure the detection of low abundance proteins.
32
  Mucins are 
high molecular weight, heavily glycosylated proteins that are prevalent in saliva.
29
  
Mucin aggregates are responsible for the viscoelastic properties of saliva.
29
  They can be 
precipitated out of the sample, reducing viscosity concerns, but since mucin-protein 
complexes can form, precipitation of the mucins can lead to a loss of protein 
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biomarkers.
17, 29
  Alpha amylase is another highly prevalent protein in saliva, and it can 
be selectively removed to allow detection of lower abundance proteins.
32
  As with the 
removal of mucins, this is only useful if the biomarker proteins are not also removed.   
If the purpose of the saliva sample is for bacterial culture, the collection 
conditions will not affect the results as much as for proteins.
17
  Because saliva is 
constantly flowing, bacteria will be constantly shed from the surfaces in the mouth.
33
  
The biggest effect on saliva samples for culture is the behavior of the patient.  Diet, tooth-
cleaning habits, and whether the patient has taken antibiotics recently will all affect the 
levels and types of bacteria found in the mouth.
33
  Some patients use more effective 
toothbrushing that is different from their usual habits prior to visiting the dentist.
33
  This 
can temporarily lower the amounts of bacteria in the mouth but, since the behavior 
usually does not continue after the visit to the dentist, levels will quickly return to 
normal.
33
  A final consideration in collecting saliva for bacterial culture is that culture 
media appropriate for the target organisms should be used during any storage or transport 
steps to keep the bacteria viable.
17
  
If the target analytes are nucleic acids, care must be taken to avoid their 
breakdown before analysis.  Salivary RNA biomarkers have been identified, and if those 
are to be measured special care must be taken to stabilize the RNA.
29
  Ambient 
temperature RNA stabilizers are available commercially and can be added to the samples 
after collection, but storage at or below -20 °C is still recommended.29, 31  DNA degrades 
more slowly, so stabilization is not as critical.
31
  If the target analytes include DNA or 
RNA from the bacteria or other microorganisms found in saliva, the same considerations 
regarding bacteria levels and patient behavior prior to collection for bacterial culture will 
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apply.  Many biomarkers, including proteins and some salivary RNA, are primarily found 
in saliva supernatant, and a centrifugation step is often incorporated before storage and 
analysis of the sample.
29
  This is not the case for genomic DNA (gDNA) from human 
cells and other microorganisms that is instead found in the solid components of saliva.
31
   
Saliva is an attractive sample for use with POC testing and LOC since it is easy to 
collect.
16, 21
  However, because of its mucin aggregates and viscous nature, saliva can be 
incompatible with microfluidic devices.
30
  Sample processing must be performed after 
collection to prevent the sample from clogging or fouling the microfluidic device.  
Freeze-thaw cycles and centrifugation can greatly decrease viscosity, but are not very 
practical in a POC setting.
29
  Filters have been used instead to remove large proteins and 
any particles from the sample.
30
  As with any other processing step, it must be verified 
that the filter doesn’t also remove the analyte from the sample.   
1.3 Immunoassays 
 For protein analytes, an immunoassay is often the analytical method of choice.
34
  
Immunoassays are tests that use antibody-antigen interactions to detect analytes in the 
sample such as hormones, cytokines, and other antibodies.
34-36
  The immunoassay 
principle was first described by Yalow and Berson in 1959 with an assay for insulin that 
used radioactive labels for detection.
37
  Their assay was a competitive immunoassay, in 
which a labeled antigen competes with unlabeled antigen in the sample for a limited 
number of antibody binding sites.  The proportion of labeled antigen bound to the 
antibodies is measured and the concentration of sample antigen determined.
35
  For a 
competitive immunoassay, the signal is inversely proportional to the analyte 
concentration.   
 8 
Another type of immunoassay is the reagent excess or sandwich immunoassay, 
which uses two antibodies.  The first antibody is immobilized onto a surface and captures 
the antigen from the sample.  A wash step removes unbound sample, and a labeled 
secondary antibody is brought in that will bind to the antigen-antibody complex on the 
surface.  Unbound secondary antibody is then washed away and the signal from the 
surface measured to determine the concentration.
35
  Because they rely on two antibodies 
specific to the antigen, sandwich immunoassays are less likely than some other types of 
immunoassays to return false positive results.
38
  The low background, due to signal 
increasing with analyte concentration, also tends to make sandwich assays more 
sensitive.
38
  One drawback to sandwich immunoassays is that finding two antibodies with 
different binding sites is difficult for some antigens.
38
  Radioactive labels were originally 
used for immunoassays, but fluorescent labels have become much more common.
34, 36, 38, 
39
  If an enzyme is used as the label for a sandwich immunoassay, it is known as an 
ELISA.
35, 40
  ELISAs add an additional step by bringing in the substrate to react with the 
enzyme and then detecting the product of that reaction.  The amplification resulting from 
the enzyme reaction makes ELISAs even more sensitive than standard sandwich 
assays.
35, 40
 
 For some analytes, immunoassays are the only practical method for quantitation.
34
  
The recognition of antigens by antibodies is extremely specific, and complex biological 
samples, such as blood, plasma, urine, and saliva can be used.
34-36
  Immunoassays can be 
designed with low limits of detection for a large number of analytes, and can be designed 
to be very fast and simple to use, with commercial kits available for many different 
analytes.
34-36
  Immunoassays can be so fast and user-friendly that they are used for POC 
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devices like home pregnancy tests.  The advantages of immunoassays make it an 
attractive technique to use in a LOC device for protein biomarkers in saliva.  All types of 
immunoassays have been adapted onto microfluidic devices, with sandwich assays and 
ELISAs being very common.
41
  Multiplexed immunoassays for more than one analyte 
have been performed on microfluidic devices.  One strategy for multiplexing is to use 
microarrays.  With microarray devices the capture antibodies are immobilized in an array 
on a surface within the microfluidic device and the assays for all analytes are performed 
simultaneously.
22, 42-46
   
 Adapting immunoassays onto microfluidic devices for POC diagnostics combines 
the advantages of immunoassays with those of microfluidics, but it requires some special 
considerations compared to immunoassays performed under standard conditions in 
microtiter plates.  The surface area-to-volume ratios in microfluidic devices are very 
high, so the characteristics of the surface and its compatibility with immunoassays are a 
concern.  Surface modification with a coating or the addition of blocking buffers to 
reagent solutions is often necessary to prevent adsorption of antigen or other reagents to 
the channel walls.
44, 47-49
  Another consideration is that at the small scale of microfluidic 
channels, fluid flow is laminar.  If diffusion is not sufficient enough to transport antigens 
or secondary antibodies to the immobilized capture antibody (for a sandwich assay), 
mixers may need to be designed into the device.
48
  Many types of mixers have been 
developed for microfluidic devices that can be used if necessary.
8-10
  A final 
consideration for immunoassays in microfluidic devices is the integration of some sort of 
internal calibration on-chip to account for chip-to-chip or run-to-run variations.
48
  Unlike 
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with microtiter plates, it can be difficult to generate a calibration curve on a microfluidic 
device. 
1.4 Detection and Identification of Bacteria 
 In addition to targeting protein analytes, diagnostic tests are also performed to 
detect bacteria and other microorganisms that cause infectious diseases. Currently, 
collected samples are usually sent to a centralized laboratory for cell culture.
14, 50-52
  After 
culture, the bacteria are identified by their phenotypic characteristics.  Morphologic 
features, growth variables, gram staining, and the growth media are just a few of the 
characteristics that can be used to identify the species.
53, 54
  To identify the particular 
strain of bacteria, susceptibility to antibiotics, protein profiles, and bacteriophage analysis 
can be used.
53, 54
  Culture-based tests are adequate for some situations, but there are many 
drawbacks.
55
  Culture methods are slow and labor intensive, often taking several days for 
results to be returned.
50, 51, 53-55
  If antibiotic susceptibility must be determined, additional 
testing time is needed.
56
  Many organisms also have similar characteristics, making 
correct identification difficult.
53
  Another problem with culture-based identification is 
that not all organisms can be cultured.
14, 56-58
  The culture methods used with diagnostic 
samples tend to be biased towards well known, well characterized species.
57
   
 An alternative to culture methods is to identify bacteria from their DNA using 
nucleic acid tests.  Nucleic acid tests can identify the bacteria in a sample in a few hours, 
eliminating the need for culture.
54, 59
  The polymerase chain reaction (PCR) is frequently 
used  to amplify DNA for nucleic acid tests.  PCR was invented in the mid-1980s by 
Kary Mullis and other scientists at Cetus Corporation.
60, 61
  PCR takes advantage of 
thermostable DNA polymerases, such as Taq polymerase, to catalyze the replication of a 
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specific DNA sequence from a template strand using oligonucleotide primers and 
deoxynucleotide triphosphates (dNTPs).  The reaction cycles through three temperature 
steps and with each cycle the amount of DNA is theoretically doubled.  The first step is 
denaturation, at a temperature from 90-95 °C, to melt the double-stranded DNA into 
single-stranded DNA.  The second step is annealing, usually at a temperature near 55 °C 
for about 30 s, to allow the primers to hybridize to the template strands.  The final step is 
extension, at a temperature near 72 °C for 0.5-3 min, where the DNA polymerase extends 
the primers and replicates the DNA sequence.  The 3-step cycle is repeated 30 or more 
times with a longer denaturation step before the first cycle and a longer extension step 
after the final cycle.  The exponential amplification from thermocycling makes PCR a 
very sensitive technique – it can be used to detect as little as one copy of template DNA 
in a sample.   
 For PCR-based diagnostic testing, samples are still sent to a centralized laboratory 
for processing.  A typical PCR test requires sample preparation steps, expensive 
equipment and reagents, and trained technicians.
1, 16, 58, 62
  Sample preparation steps are 
necessary because template DNA often needs to be released from the nucleus of the cells 
and because PCR inhibitors are often present that, if not removed, may cause false 
negatives.
59, 63
  These labor-intensive steps mean that at centralized labs the tests are 
usually performed once a day in large batches, so the minimum time for obtaining results 
is about 24 hours.
56, 58
  Adapting PCR onto a microfluidic device can make it amenable to 
POC diagnostics.  Some advantages of microfluidic PCR tests over tube-based 
procedures include lower consumption of expensive reagents, faster cycling times, lower 
costs per test, and automated processing by minimally trained personnel.
11, 14, 51, 64-67
  A 
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LOC incorporating PCR for diagnostic testing could be portable, with disposable chips to 
eliminate contamination between samples.  Devices could also incorporate parallel 
processing units to increase throughput and identify multiple strains or species of bacteria 
simultaneously.
50, 62, 66, 67
 
 As with any microfluidic device, the exact design and materials used in a PCR 
chip will vary depending on the application.  Regardless of the application, for PCR 
microfluidics there are two main design strategies.  The first strategy is stationary 
chamber PCR.  The PCR solution is kept stationary inside a reaction chamber and the 
temperature of the chamber is cycled.  This design is similar to tube-based PCR testing, 
and has the advantages of simple chip configuration and great flexibility in the length of 
the thermocycling steps and in the number of cycles.
1, 14, 66, 67
  The second strategy is flow 
through PCR.  The PCR solution continuously flows through different zones of the chip 
that are held at constant temperatures.  This design can achieve extremely fast 
thermocycling times since only the thermal mass of the sample must be heated and 
cooled rather than the entire chip.  A major drawback of this design is that the number of 
cycles is usually fixed by the channel layout so it is not as flexible as the chamber 
design.
1, 14, 66, 67
  Either chip design can be integrated with different types of sample 
processing, heating strategies, and post-PCR analysis and detection of products.
67
   
 No matter what design and materials are chosen for a microfluidic PCR device, 
preventing PCR inhibition is a major concern.  As with immunoassays, the high surface 
area-to-volume ratios found in microfluidic devices can be a problem.  Adsorption to the 
channel surfaces can be a problem not only for template DNA in the sample but also for 
the primers and the Taq polymerase.
63, 68
  Adsorption of any of the reagents to the 
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channel surfaces will inhibit PCR, so various passivation strategies are used to reduce or 
prevent the adsorption.  Bovine serum albumin (BSA) and polyvinylpyrrolidone (PVP) 
are two common PCR additives used for dynamic surface passivation.
67, 68
  Static surface 
passivation by coating the channels with a PCR friendly substance is another way to 
reduce adsorption.
63, 67
   Inhibition can also be caused by materials used in the fabrication 
of chips, so the fabrication choices may be restricted if a reaction is particularly 
sensitive.
63, 67
  Sample components other than the target DNA are another source of 
inhibition that can be addressed by integrating sample preparation onto the microchip.
69-73
  
The extraction technique used will depend on the application.   
1.5 Research Goals and Objectives 
 The focus of the research discussed in this dissertation is the development of a 
POC microfluidic device that uses saliva samples to diagnose and monitor pulmonary 
diseases such as asthma and cystic fibrosis, as well as respiratory infections that are 
common in patients with pulmonary diseases.  The targeted saliva components are 
cytokines, chemokines, and bacterial species that are either biomarkers of disease or 
causes of infections.  The device should be useable without specialized training and 
should be fully integrated and self-contained, without the need for extensive off-chip 
sample preparation or signal detection.  It was determined that two devices, one targeting 
proteins via multiplex immunoassays and the other targeting bacterial DNA via PCR 
would be developed.  The potential merging of the two devices into a single device was 
one of the design criteria, but it was not pursued.  PDMS was chosen as the material of 
choice because it is inexpensive, optically transparent for fluorescence detection 
 14
techniques, easy to fabricate devices and prototype potential chip designs, and it is 
generally compatible with biological systems.
74, 75
   
This project is part of a collaboration with the Walt group at Tufts University 
(biomarker screening and immunoassay development), Ahura Scientific (control 
instrument development and data acquisition), and the Brodley group at Tufts University 
(automated data analysis and data mining).  Other collaborators include the Oppenheim 
group at Boston University Medical Center, who have been collecting and tracking saliva 
samples, and clinicians from Boston University Pulmonary/Boston Medical Center and 
the Children’s Hospital at Harvard University who have been recruiting asthma and 
cystic fibrosis patients to donate samples for the study.   
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CHAPTER 2 
MICROFLUIDIC BEAD-BASED IMMUNOASSAY CHIP 
2.1 Introduction 
Microfluidic immunoassays for POC diagnostics have been developed with many 
different strategies.  Chips have been fabricated using silicon, glass, and polymers as the 
base material, although some materials are better suited for POC immunoassays than 
others.
1, 2
  Silicon does not make a very good substrate since proteins tend to bind to the 
surface and it is not optically transparent in the UV/visible region of the spectrum often 
used for optical detection of immunoassay results.
1
  Glass is optically transparent and has 
better surface chemistry for immunoassays than silicon, but polymers, such as PDMS, are 
also optically transparent and are especially well-suited for mass production.
3
  Polymer 
chips also tend to have reduced manufacturing costs compared with silicon or glass 
devices with the more expensive fabrication processes only used for the development of 
the mold.  The mold can then be used to make many highly reproducible castings for 
chips.
1-3
   
The type of immunoassay used also varies between chips.  Since non-competitive 
immunoassays such as sandwich assays tend to be more sensitive, they are often used in 
microfluidic chips.
4
  These types of immunoassays require an immobilized capture 
antibody on a surface, generally one of the channel surfaces in a microfluidic chip.  
Antibodies can be immobilized through microcontact printing or by chemically tethering 
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the antibody to the surface.
1, 2, 5
  With any immobilization method used, the antibodies 
need to be oriented properly on the surface to capture antigen from the sample.
1, 2, 5
 
The type of signal generated for the detection of antigen varies as well.  
Fluorescence, surface plasmon resonance, and electrochemical detection methods are the 
most common.
1, 2, 4
  Fluorescence detection is easy to integrate into an immunoassay and 
it has high sensitivity which makes it the most common form of detection.
1, 2, 5
  ELISAs 
can be performed with a substrate and enzyme that generate a fluorescent product for 
even greater sensitivity than standard fluorescence detection.
6
  One device described was 
made from a glass slide, used a streptavidin-biotin linkage to immobilize antibodies on a 
surface, and then used fluorescently labeled reporter probes to detect cancer markers 
from saliva samples.
7
  Another device was made from polymers and incorporated a 
lateral flow strip with immobilized synthetic HIV envelope peptides to capture antibodies 
to HIV from saliva samples that were then detected with fluorescently labeled reporters.
8
 
These are just two examples of the many applications and sample types that microfluidic 
immunoassays can be designed for.   
Since antibody-antigen interactions are very specific, most immunoassays can 
detect only one analyte.  If multiplexed detection from the same sample is desired, 
antibodies for multiple antigens can be immobilized to a surface in a microarray.  
Microarrays allow many analytes to be evaluated simultaneously, saving time and 
reducing the sample volume needed since only one assay is performed.
4, 9-11
  Microfluidic 
devices can incorporate microarrays and the technique has been demonstrated for many 
applications.
3, 12-14
  While microarrays of immobilized antibodies can be fabricated, the 
current technology for spotting the antibodies is labor-intensive and requires high-
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precision, and the antibody-spotting technology makes customizing the selection of 
antibodies used in each chip difficult.
11, 15-17
   
An alternative to immobilizing capture antibodies directly onto a surface is to 
couple antibodies to microspheres.  Microsphere-based immunoassays have a number of 
advantages over planar assays including better reproducibility in the attachment of 
capture antibodies to the surface, more flexibility in surface chemistry, and shorter 
analysis times.
11, 18, 19
  Microspheres also have a high surface-to-volume ratio leading to a 
greater number of capture antibodies available and therefore higher sensitivity compared 
to planar immunoassays.
15, 16, 20
  Microspheres can also be used to form microarrays for 
multiplexing, and having a prepared library of microspheres with capture antibodies for 
different analytes means an array can be easily customized for a particular set of targets.  
Microarrays of antibody-coupled microspheres can be formed by loading microspheres 
into known locations, or by randomly loading a mixture of microsphere types and 
decoding the type of microsphere in each location afterwards.
16, 18-22
  Decoding of 
random arrays can be done by doping the microspheres with varying levels of one or 
more fluorescent dyes or even by photobleaching a barcode onto each microsphere if they 
are large enough.
11, 16, 23
 
The Walt group at Tufts University has developed microsphere-based 
immunoassays that use fiber optic bundles to form microarrays.
16, 24, 25
  Sets of 
microspheres, or beads, are functionalized with different capture antibodies.  Mixtures of 
beads with different capture antibodies are randomly loaded into fiber optic arrays to 
perform multiplexed immunoassays.  Each type of microsphere is encoded with a unique 
concentration of europium (Eu
3+
) dye, which allows them to be identified by fluorescence 
 24
intensity after they are loaded into an array.
24-27
  Multiple encoding dyes can be used if 
the multiplexed assay calls for more bead types than can be distinguished using a single 
dye.
23, 28
  The end of the fiber optic bundle containing the array is exposed to reagent 
solutions over the course of a sandwich assay and the fiber is finally imaged, both for 
decoding and signal detection, using a custom-built epi-fluorescence microscope with a 
charge-coupled device (CCD) camera.
23
  The Walt group used conventional ELISA 
methods to identify ten salivary cytokines and chemokines that are potential biomarkers 
for pulmonary diseases, such as asthma and cystic fibrosis, and developed antibody-
functionalized microspheres that were used in fiber optic microarrays to simultaneously 
measure all ten analytes in saliva supernatant samples from patients with pulmonary 
diseases.
23, 29
   
 In this chapter the adaptation of the Walt group’s microsphere-based 
immunoassay onto a microfluidic chip is described.  The PDMS/glass hybrid chip 
contains an 896-well microarray fabricated into a single PDMS layer that also includes 
all the fluidic channels needed to deliver reagents for the sandwich assay to the array.  
The optimization of the assay is described and limits of detection in buffer and saliva 
supernatant were determined for two cytokines.   
2.2 Materials and Methods 
Materials and Reagents 
Sylgard 184 PDMS was obtained from Dow Corning (Midland, MI).  PDMS was 
prepared according to the manufacturer’s recommendation with a 10:1 polymer/cross-
linker ratio.  Trichloro-(1H,1H,2H,2H-perfluorooctyl)silane, 97% (perfluorooctyl silane), 
poly(ethylene glycol) (PEG) with an average molecular weight of 200 g/mol (PEG 200), 
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polyvinylpyrrolidone (PVP) with an average molecular weight of 10,000 g/mol, 10x 
phosphate buffered saline solution (PBS), tris buffered saline with 0.05% Tween 20 
(TBS/Tween 20), and DNase/RNase free polyurethane amplification tape (PCR tape) 
were purchased from Sigma-Aldrich (St. Louis, MO).  Fisherbrand plain glass 
microscope slides (75 mm x 25 mm, 990 μm thick) and isopropyl alcohol were purchased 
from Thermo Fisher Scientific (Waltham, MA).  SEA Block blocking buffer, SuperBlock 
blocking buffer, Protein Free blocking buffer, Blocker BSA (10% BSA) in PBS, PBS 
Starting Block blocking buffer, and TBS Starting Block blocking buffer were purchased 
from Pierce Biotechnology, Inc. (Rockford, IL).  PEG with an average molecular weight 
of 10,000 g/mol (PEG 10k) was purchased from Alfa Aesar (Ward Hill, MA).  Buffered 
oxide etchant (BOE), 10:1, was purchased from Transene (Danvers, MA).  2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane, 90% (PEG-silane) was purchased 
from Gelest (Morrisville, PA).  Streptavidin-Alexa Fluor 488 (AF488) conjugate was 
purchased from Invitrogen (Carlsbad, CA).  Purified recombinant human vascular 
endothelial growth factor (VEGF), interleukin-8 (IL-8), and biotin-labeled polyclonal 
detection antibodies for each cytokine were purchased from R&D Systems, Inc. 
(Minneapolis, MN).  Cytokines and antibodies were reconstituted according to the 
manufacturer’s instructions.  Buffer solutions of 1x PBS containing 0.1% PEG 10k 
(PBS/PEG10k) were prepared from a 10x stock solution diluted with deionized (DI) 
water filtered with a NANOpure Diamond water purification system (Barnstead 
International, Dubuque, IA).   
Antibody coupled microspheres were provided by collaborators in the Walt group 
at Tufts University and were made in a manner previously described.
23
  Briefly, 3.1 m 
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diameter amine-functionalized microspheres are encoded with Europium (III) 
thenoyltrifluoroacetonate trihydrate at concentrations of either 1.0, 0.5, 0.125, or 0.025 
M. These four concentrations can be differentiated based on fluorescence emission 
intensity upon UV excitation.  After encoding, four different cytokine capture antibodies 
are attached to the different sets of microspheres after which they are stored in TBS 
Starting Block blocking buffer with 0.05% sodium azide at 4 °C, protected from light.   
Chip Fabrication 
The chips were fabricated by first making a master mold of the chip design in 
glass followed by making a complementary mold of the master in PDMS. The final 
PDMS chips were prepared from the complementary PDMS mold.  This has recently 
been described in detail.
30
  Glass master molds were fabricated using a combination of 
wet chemical etching and focused ion beam (FIB) milling.  Channels were patterned onto 
a glass substrate using standard photolithography techniques and etched to a depth of 30 
m using 10:1 BOE.  A 50 nm thick layer of chromium was sputtered onto the glass 
substrate using an Ion Deposition/Sputter System (South Bay Technology, Inc., San 
Clemente, CA).  Microarrays were milled using a Helios 600 Nanolab Dual Focused Ion 
Beam System (FEI, Hillsboro, Oregon).  Galium ions at an energy of 30 keV and current 
of 21 nA were used to mill individual microwells to a depth of 2.95 m and diameter of 
2.75 m with a well center-to-center spacing of 8 m.  Array patterns from 100 wells 
(10x10) up to 896 wells (28x32) were milled.  Assay optimization and limit of detection 
determination were performed on chips with 896 well arrays.   
The glass master was treated with oxygen plasma at 18W for 1 min (Harrick 
Plasma, model PDC-32G, Ithaca, NY) and placed in a vacuum desiccator with 40 μL of 
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perfluorooctyl silane.  Vacuum was applied for approximately 5 min to allow silane 
vapor to fill the desiccator and then it was sealed for 20-30 min.  This treatment reduced 
PDMS adhesion to the master.  A secondary mold of the master was cast in PDMS by 
placing the master channel-side up in a larger mold form and covering it with PDMS to a 
5-10 mm depth.  The PDMS-filled mold form was placed in a vacuum desiccator with 
vacuum applied for 15-20 min to degas the PDMS.  The mold was then cured for 30 min 
at 60 °C followed by 15 min at 95 °C.  After cooling, the PDMS mold was removed from 
the mold form and separated from the master, and the edges were trimmed with a razor 
blade.   
The PDMS secondary mold was silanized in the same manner as the glass master, 
but with a shorter 5 s plasma treatment step.  The PDMS layer of the microfluidic chip 
was made by pouring ~4 mL of PDMS into the mold, degassing under vacuum, placing a 
glass slide over the top of the mold to push out excess PDMS and to give the chip a 
reproducible thickness, and then curing at 95 °C for 15 min.  The PDMS chip layer was 
then separated from the mold and trimmed with a razor blade.  The silanization prevented 
the PDMS chip layer from adhering to the PDMS mold.   
Access holes were made with a 3 mm diameter biopsy punch (Sklar Instruments, 
West Chester, PA) at the ends of each channel to form fluid reservoirs.  The PDMS layer 
was irreversibly bonded to a glass microscope slide to give a completed PDMS/glass 
hybrid chip.  Before bonding, PDMS layers were cleaned with isopropanol and dried with 
nitrogen.  Microscope slides were cleaned with a 5% Contrad solution (Decon Labs, King 
of Prussia, PA), rinsed with DI water, and dried with nitrogen.  Both layers were then 
plasma treated at 18 W for 12 s and irreversibly bonded by gently pressing the channel 
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side of the PDMS layer onto the glass slide.  Bonded chips were allowed to stabilize at 
room temperature for at least 1 day before use.   
An image of a chip, an SEM image of an FIB milled array, and a schematic of the 
cross section of a chip are shown in figure 2.1.  The chip has 4 reagent reservoirs to 
introduce sample, secondary antibody, AF488, and wash buffer.  Vacuum is applied to a 
fifth waste reservoir to effect fluid flow.  The reagent reservoirs individually connect to 
the main channel that includes the microwell array followed by a serpentine path to the 
waste reservoir. The serpentine path has a large enough volume such that delivered 
reagents used during an assay will remain on-chip.  This will prevent the chip reader 
(control instrument) from becoming contaminated with sample or other reagents.  The 
reader instrument will use pinch valves to automate fluid handling on-chip.  When 
actuated, the valves press on the PDMS above a channel, pinching it closed.  Valving 
locations are shown in figure 2.1A.  The assay development and limit of detection 
determination described in this chapter were performed without valves.   
Chip Preparation 
Prior to running an assay, the chip’s microwell array was loaded with antibody-
functionalized microspheres.  The chip was first filled with buffer (PBS/PEG10k unless 
otherwise noted) by filling all 4 reagent reservoirs and applying vacuum to the waste 
reservoir.  Then a slurry containing a mixture of different antibody-coupled microspheres 
was introduced into the array chamber by putting the bead mixture into the sample 
reservoir and applying vacuum to the waste.  Once in the array chamber, beads were 
pushed into wells by applying pressure on the PDMS layer directly over the array, 
forcing beads into individual microwells.  Pressure was applied by placing a thumb or 
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finger on the PDMS over the array and pressing down against the glass.  The extent of 
array loading was monitored with a fluorescence microscope and pressure was applied 
repeatedly until the array was sufficiently loaded (usually to a 90% efficiency or better).  
Unloaded microspheres were washed away with buffer.  The channels were then filled 
with fresh buffer (PBS/PEG10k unless otherwise noted), the reservoirs were sealed with 
PCR tape to prevent evaporation, and the chips were stored in the dark at 4°C for at least 
1 hour before using for an assay.   
Assay Procedure 
The assay procedure was adapted from the fiber optic immunoassays developed at 
Tufts University.
23
  Protein assays were performed with the following procedure unless 
otherwise noted.  Reagent solutions were introduced onto the chip through all four 
reagent reservoirs because these assays were performed without valves.  Each solution 
was added to the reservoirs just before it was delivered, and excess reagent was removed 
from the reservoirs (with vacuum) just before the next reagent was added.  Sample 
solution (20 μL) containing cytokines diluted in PBS/PEG10k buffer was added to the 
reservoirs of the chip and delivered to the microarray.  The array was incubated with the 
sample for 20 min.  The secondary antibody solution, also diluted in PBS/PEG10k buffer, 
was introduced into the chip in the same manner as the sample followed by a 15 min 
incubation.  AF488 was then added to the chip followed by a 10 min incubation. Finally, 
the wash buffer, TBS/Tween 20, was added to the chip and the array and channels were 
rinsed for 10 min by continuously flowing the wash buffer over the array.  After rinsing, 
the top and bottom surfaces of the chip were cleaned with ethanol and the array was 
imaged.  The chips were protected from light during the entire assay.  
 30
A schematic of the sandwich assay is shown in figure 2.2.  During the sample 
incubation, the cytokines are captured by the antibodies attached to the beads.  The 
biotinylated secondary antibodies then attach to the antigen-antibody complex on the 
beads during the secondary antibody incubation.  During the AF488 incubation, the 
streptavidin in the AF488 forms a linkage with the biotin on the secondary antibodies and 
labels the antigen-antibody sandwich with a fluorescent tag.  The final wash removes the 
excess AF488 and the AF488 bound to the antigen-antibody complex can be detected 
with fluorescence microscopy.   
For experiments using saliva supernatant as samples, whole saliva was collected 
from healthy volunteers by having them drool into a clean centrifuge tube.  The samples 
were centrifuged at 4000 rpm for 30 min.  Aliquots of saliva supernatant were spiked 
with cytokine standards for limit of detection determinations.   
Image Collection and Analysis 
Arrays were imaged with a Nikon Eclipse Ti-U inverted microscope with a Nikon 
Intensilight C-HGFIE mercury light source (Melville, NY) and collected with a Cascade 
II 512 electron multiplying CCD (EMCCD) camera (Photometrics, Tucson, AZ).  A 
custom optical filter cube (Chroma Technology Corp., Rockingham, VT) was used for 
fluorescence imaging of the europium encoding dye (ex=365 nm, em=605 nm) and a 
Nikon filter cube B-2E/C was used for collection of the AF488 signal (ex=488 nm, 
em=520 nm).  Two images were acquired for each array: an encoding image (ex=365 
nm, 100 ms exposure), and an assay image (ex=488 nm, 8 s exposure).  Encoding and 
assay images were acquired using Micromanager
31
 and analyzed using ImageJ
32
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(National Institutes of Health, USA), IgorPro (WaveMetrics, Inc., Lake Oswego, OR), 
and OriginPro (OriginLab Corp., Northampton, MA).   
ImageJ was used to decode images and determine signal intensities.  For both 
encoding and assay images, microsphere intensities are spread over ~4 pixels but only the 
intensity of the brightest pixel is used.  Encoding images were used to identify 
microsphere types so that individual cytokine signal intensities could be determined from 
the assay images.  For each array, signal intensities from microspheres of the same type 
were averaged to obtain the raw signal.  Values not within 2.5 standard deviations from 
the mean were discarded and the remaining values were averaged to obtain the corrected 
signal.  This is a technique commonly used with clinical chemistry data to eliminate false 
positives and negatives and other outliers, although outliers can easily inflate the standard 
deviation to the point that they are not discarded.
33
  A microsphere type for which no 
analyte was present was used as a control to determine non-specific binding.  The net 
signal for a given cytokine was calculated by subtracting the corrected control bead 
signal from the corrected target analyte bead signal.  Noise values were calculated in 
IgorPro by finding the standard deviation of the pixel intensities in an area of the 
background outside the array.  The net signal is divided by the noise to calculate the 
signal to noise ratio (S/N).  A set of encoding and assay images from a VEGF assay is 
shown in figure 2.3, with selected VEGF and control (IL-8) beads circled in both images.  
Limit of detection data were fit to a 4-parameter logistics equation using OriginPro.  
Theoretical limits of detection were based on a S/N of 3.   
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2.3 Results and Discussion 
Surface Passivation 
The surface of PDMS is hydrophobic, making it prone to nonspecific adsorption 
of biomolecules such as proteins.
3, 34-38
  Surface passivation of both the PDMS and glass 
surfaces is essential to ensure compatibility with the biological sample matrix and assay 
reagents.  Many strategies to prevent protein adsorption and increase biocompatibility of 
these surfaces have been described.
36-41
  Both static and dynamic surface coatings were 
investigated to reduce non-specific adsorption to the channel walls during assays, but 
dynamic coatings were favored due to their simplicity and faster chip preparation times.  
Dynamic coatings are buffer additives that are thought to reduce non-specific adsorption 
by preferentially adsorbing to the surface instead of the protein.
42
   
Eight different dynamic coatings and a static silane coating were evaluated: four 
commercial blocking buffers (10% Blocker BSA, SuperBlock, Protein Free, and SEA 
Block), PBS with 0.1% BSA, PBS with 0.1% PVP, PBS with 0.1% PEG 200, 
PBS/PEG10k, and a PEG-silane coating.  One chip was used to test each coating.  For 
these experiments, the buffer used for chip preparation and during the assay was the 
buffer containing the dynamic coating listed above instead of the PBS/PEG10k described 
in section 2.2.  The PEG-silane coated chip was prepared following the procedure 
described by Sui, et. al.
38
  Briefly, after the chip was bonded, a 5:1:1 mixture of 
H2O/H2O2/HCl was continuously washed through the channels for 5 min, the channels 
were rinsed with DI water and dried with air, the channels were filled with neat PEG-
silane and incubated for 30 min at room temperature, and then the channels were rinsed 
with DI water again and dried with air.  PBS with 0.1% BSA was used as the buffer for 
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the PEG-silane coated chip.  After bead loading, all channels were filled with the 
appropriate buffer and incubated for at least 1 h at 4 °C.  Reagent solutions were prepared 
with each of the buffers using VEGF as a model analyte.  500 pg/mL VEGF, 3 μg/mL 
anti-VEGF, and 20 μg/mL AF488 were used.  The assay was performed at room 
temperature with a 1 h sample incubation, 30 min secondary antibody incubation, 10 min 
AF488 incubation, 10 min wash with assay buffer, and a 10 min wash with TBS/Tween 
20.   
The results of these assays are shown in figure 2.4.  PBS/PEG10k buffer was 
found to be the best of all the coatings tested, and therefore was used for all future 
experiments.  The S/N was 2.1 times higher than that for the SEA block dynamic coating, 
which had the second highest S/N, and 5.9 times higher than that for the static PEG-
silane coating.  The PBS with PEG 200 and PEG 10k buffers were found to result in the 
lowest noise values and were among the assays with the lowest control signals.  The 
chips using other blocking buffers had higher control bead signal intensities and higher 
noise values.  This combination led to lower S/N ratios compared to that from the 
PBS/PEG10k blocking buffer.   
Incubation Temperature 
The effect of incubation temperature on assay performance was also investigated.  
According to Ekins’ ambient analyte theory of immunoassay behavior, only a small 
fraction of the analyte molecules in solution are captured by their complementary 
antibodies for immunoassays in a microarray format.
43, 44
  It has also been found that 
most microarray immunoassays exhibit kinetic limitations and are diffusion limited.
45
  
Some of the ways to overcome diffusional limitations in microarrays are to incorporate 
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stirring into the assay design, to decrease the size of the microspots, and to change the 
reaction conditions in order to increase the diffusion coefficients of the sample and 
reagents.
45
  Since the size of the microspots for our assay is the size of the microspheres, 
decreasing their size is not an optimal solution.  Many mixer designs have been 
developed for microfluidic chips, but incorporating a mixer would add complexity to the 
device in both design and operation.
46, 47
  Changing the reaction conditions to affect the 
diffusion coefficient is much more easily done.  The diffusion coefficient is directly 
proportional to temperature.
48
  Performing the incubations at an elevated temperature 
should increase the diffusion coefficients and may produce increased signals if the 
immunoassay is diffusion limited.   
 Two different incubation temperatures were evaluated: room temperature (~25 
°C) and 37 °C.  37 °C was evaluated because it is the normal human body temperature.  
Four chips were used to test each incubation temperature.  For incubations at 37 °C, the 
chips were placed in a 37 °C oven.  Wash steps were performed at room temperature for 
all of the chips.  Reagent solutions were prepared in PBS/PEG10k buffer using VEGF as 
a model analyte.  500 pg/mL VEGF, 3 μg/mL anti-VEGF, and 20 μg/mL AF488 were 
used for this assay.  The assay was performed with a 1 h sample incubation, 30 min 
secondary antibody incubation, 10 min AF488 incubation, 10 min wash with 
PBS/PEG10k buffer, and a 10 min wash with TBS/Tween 20.  The average S/N for 
VEGF assays with incubations at 37 °C was ~33% higher than that for assays with 
incubations at room temperature. All future experiments used an incubation temperature 
of 37 °C.   
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Assay Step Elimination 
Assay time is an important consideration for a POC device.  If results are acquired 
while the patient is still at the doctor’s office and treatment decisions based on those 
results can be made without the need for a follow-up visit, patient outcomes will improve 
for population groups that often do not return for their test results.
49-51
  In order to 
decrease the total assay time and the complexity of the chip design, eliminating the first 
buffer wash with PBS/PEG10k was tested.  VEGF was again used as the model analyte 
with all reagent concentrations and assay steps the same as above. 
Eliminating the first buffer wash resulted in an ~98% increase in S/N over the 
original procedure.  The increase may be due to less time for the antibody-antigen 
interactions to dissociate.  The reactions between antibodies and antigens are in 
equilibrium, so if a complex dissociates during a wash step, it will not remain nearby and 
be recaptured by the antibody.  Due to the increase in S/N from the elimination of the 
first wash step, it was eliminated from all future assays.   
Incubation Time 
Secondary antibody, sample, and AF488 incubation times were optimized 
individually with VEGF as the model analyte.  Ideally, assay conditions would be 
optimized for each individual analyte.  However, for the multiplexed bead array format, it 
is necessary to have a single incubation time for all analytes.  It would not be possible to 
use a 30 min sample incubation for one analyte and a 60 min sample incubation for 
another analyte if the analytes are simultaneously measured with the same microarray.  In 
this instance, VEGF was chosen as the cytokine for optimizing these parameters.  
Reagent concentrations of 500 pg/mL VEGF, 3 μg/mL anti-VEGF, and 20 μg/mL 
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AF488, and an incubation temperature of 37 °C were used for all incubation time 
optimization experiments.  One chip was used to test each incubation time.   
For secondary antibody incubation time optimization, the secondary antibody 
incubation time was varied from 1 to 60 min.  A 1 h sample incubation, 10 min AF488 
incubation, and 10 min wash with TBS/Tween 20 were used.  The results are shown in 
figure 2.5A.  As expected, an increase in S/N was observed with increasing incubation 
times, but without much improvement beyond 20 min.  In addition to improving the 
overall results, the goal for the incubation time optimizations was to limit the total assay 
time to less than 1 h.  In the interest of balancing sensitivity with total assay time, a 15 
min secondary antibody incubation was used for all future assays.  Although an assay 
was not performed with a 15 min incubation time, this was expected to deliver results 
nearly as high as the 20 min incubation time while allowing more time for the sample and 
AF488 incubations.   
For sample incubation time optimization, the sample incubation time was varied 
from 1 to 120 min.  A 15 min secondary antibody incubation, 10 min AF488 incubation, 
and a 10 min wash with TBS/Tween 20 were used.  The results are shown in figure 2.5B.  
As expected, an increase in S/N was observed with increasing incubation times, but with 
less dramatic increases when the incubation time was longer than 20 min.  With an 
increase from 10 min to 20 min the S/N increased 35%, but with an increase from 20 to 
30 min the S/N only increased 13%.  Although a large increase was observed at the 60 
min incubation time, it was not present at 120 min.  In order to balance the overall assay 
time with assay sensitivity, a 20 min sample incubation was used for all future assays.   
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For AF488, the incubation time was varied from 1 min up to 20 min, with a 20 
min sample incubation, 15 min secondary antibody incubation, and a 10 min wash with 
TBS/Tween 20.  Despite repeated attempts, no consistent trend in the S/N relative to 
AF488 incubation time was observed.  For future assays the incubation time was 
therefore left at 10 min, the optimal AF488 incubation time found for the microspheres at 
Tufts University.  These incubation time optimizations, along with the elimination of the 
first wash step, resulted in a reduction of total assay time from 2 h down to 55 min, less 
than half the original length of time.   
Reagent Concentration 
Secondary antibody and AF488 concentrations were optimized individually with 
VEGF as the model analyte.  The secondary antibody concentration should be optimized 
individually for each analyte, but, as with incubation times, the same concentration of 
AF488 must be used by all analytes measured in the same bead array.  The reagent 
concentration optimization assays were performed with a 20 min sample incubation, 15 
min secondary antibody incubation, 10 min AF488 incubation, and a 10 min TBS/Tween 
20 wash, an incubation temperature of 37 °C, and a sample concentration of 500 pg/mL 
VEGF.  One chip was used to test each reagent concentration.   
For secondary antibody concentration optimization, 0.5, 1, 2, 3, and 4 μg/mL anti-
VEGF solutions were tested.  An AF488 concentration of 20 μg/mL was used.  The 
results are shown in figure 2.6A.  An initial increase in S/N is observed as the secondary 
antibody concentration is increased from 0.5 μg/mL to 2 μg/mL with no clear trend at 
higher concentrations, indicating that the greatest binding of secondary antibody to the 
antibody-antigen complex occurs at relatively low concentrations.  Since significant 
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increases in background signal or noise were not seen at high concentrations, the 
secondary antibody concentration was left at 3 μg/mL for future assays in case larger 
antigen concentrations should require more secondary antibody. 
For AF488 optimization, the AF488 concentration was varied from 0.5 μg/mL up 
to 40 μg/mL.  A secondary antibody concentration of 3 μg/mL was used.  The results are 
shown in figure 2.6B.  As expected, the S/N increases with increasing AF488 
concentration.  As the concentration of AF488 increases, the likelihood of non-specific 
binding of the dye also increases, increasing background signal and noise.  The error was 
also much greater for the assay at the highest concentration, 40 μg/mL, so the AF488 
concentration was left at 20 μg/mL for future assays.   
Limit of Detection 
Limits of detection (LOD) were determined for VEGF and IL-8 in buffer and 
saliva supernatant solutions using the optimized conditions listed in table 2.1.  The range 
of sample concentrations for the studies was 1 pg/mL up to 500 pg/mL.  Each 
concentration was tested with one chip.  The S/N results were fit to the following 4-
parameter logistics equation
11
 where y is the S/N and x is the analyte concentration.  This 
equation was then used to find the theoretical LOD at a S/N of 3.  The results for VEGF 
in buffer are shown in figure 2.7.   
The results of the LOD studies are shown in table 2.2.  The LOD for VEGF and 
IL-8 in buffer were found to be 0.3 and 2.5 pg/mL, or 15 and 150 fM, respectively.  The 
LODs were 1.2 and 3.9 pg/mL, or 130 and 500 fM, for VEGF and IL-8 respectively in 
y = d +
a  d
1+ x c( )
b
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saliva supernatant.  The higher LODs in saliva supernatant are probably due to increased 
non-specific binding seen with the saliva samples, likely from the presence of mucins and 
other glycoproteins in the saliva matrix.  For VEGF, ELISA kits can be purchased with 
ranges extending down to ~100 fM (Thermo Scientific, Rockford, IL).  Reported 
concentrations of VEGF in saliva range from 10-100 pM for healthy individuals to 5-170 
pM in asthmatic patients.
29, 52
  The theoretical LOD for VEGF using this assay is well 
below that, even in saliva supernatant.  For IL-8, ELISA kits can be purchased with 
ranges extending down to ~3 pM (Thermo Scientific, Rockford, IL).  Reported 
concentrations of IL-8 in saliva vary from 29-125 pM for healthy individuals, 85-390 pM 
for oral cancer patients, and 20-130 pM for patients with burning mouth syndrome.
7, 53-55
  
The theoretical LOD for IL-8 in saliva supernatant using this assay is well below those 
ranges.  Since the LODs for VEGF and IL-8 are well below physiological levels, the 
decreased incubation times used to keep the total assay time under 1 h do not need to be 
increased.   
2.4 Conclusions and Future Directions 
The microsphere-based multiplexed immunoassay developed by the Walt group 
has been incorporated onto a microfluidic device that is easily fabricated and disposable.  
This is the first step in making a POC device to detect protein biomarkers in saliva 
samples.  The microfluidic chips were designed with automation in mind, through a 
reader being developed by Ahura Scientific.  Compatibility with a reader instrument led 
to the incorporation of separate reagent reservoirs, channels long enough to accommodate 
valves, and a long waste channel to prevent reader contamination.  The chips were 
fabricated out of PDMS because it is optically transparent for fluorescence detection, 
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inexpensive compared to chips made of glass or silicon, and its flexibility means 
microspheres can be easily loaded into an array and the channels can be easily pinched 
closed for valving.  Assay optimization was performed with VEGF as a model analyte, 
and LODs in buffer and saliva supernatant were found for both VEGF and another 
cytokine, IL-8.  
Although my work on this microfluidic immunoassay chip did not continue any 
further, Patty Dennis, a postdoctoral associate in the Ramsey group, continued the work.  
One of her experiments investigated the shelf life of chips loaded with microspheres, 
another consideration for using the chips in a clinical setting.  Chips were successfully 
stored for 48 days, so clinicians may be able to keep more than a month’s supply of chips 
on hand.  A new molding strategy has also been developed that uses deep reactive-ion 
etching (DRIE) to etch silicon wafers to make the master molds.  This eliminates the need 
to FIB mill the microwell arrays and to make complementary PDMS molds, greatly 
simplifying the chip fabrication.   
One of the biggest problems with the continuing development of this chip has 
been the antibody-coupled microspheres used to make the microarray.  The batch of 
microspheres used for the experiments described in this chapter was exhausted soon after 
the experiments were completed.  Subsequent batches produced results greatly inferior to 
those seen with the original batch, even after reoptimizing the assay conditions.  Work 
eventually continued with microspheres that do not perform as well, but are the best 
available.  Chips are currently being sent to Tufts University for testing with the reader 
instrument and to be loaded with beads and sent on to clinicians for real-world testing.  
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The Walt group has successfully used the chips to perform a multiplexed immunoassay 
with 8 analytes (data not published).   
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2.5 Tables and Figures 
 
Table 2.1.  Optimized conditions for microfluidic bead-based immunoassays. 
Condition Optimized Value 
Incubation Temperature 37 °C 
Sample Incubation Time 20 min 
Secondary Antibody Concentration 3 μg/mL 
Secondary Antibody Incubation Time 15 min 
AF488 Concentration 20 μg/mL 
AF488 Incubation Time 10 min 
TBS/Tween 20 Wash Time 10 min 
 
 
Table 2.2.  Theoretical limits of detection for individual cytokines in buffer and saliva.  
Assays were performed using the optimized assay conditions listed in table 2.1.   
Limit of detection  
in buffer 
Limit of detection in  
saliva supernatant  
Cytokine 
pg/mL fM pg/mL fM 
VEGF 0.3 15 2.5 130 
IL-8 1.2 150 3.9 500 
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Figure 2.1.  An image of the immunoassay chip (A), an SEM image of an FIB milled 
array (B), and a schematic of the cross-section of a chip (C).  The reservoirs in (A) are 3 
mm in diameter.  The schematic (C) is not to scale.   
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Figure 2.2.  Schematic of the sandwich assay used with the Walt group microspheres.  
The antibody-functionalized microspheres are incubated with sample and the antibodies 
on the beads capture the target analytes.  Biotinylated secondary antibodies bind to the 
antigen-antibody complex, forming a sandwich.  The streptavidin in the AF488 binds to 
the biotin on the secondary antibodies, fluorescently labeling the sandwich.  The excess 
AF488 is then washed away and the signal can be measured with fluorescence detection.   
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Figure 2.3.  Example (A) encoding and (B) assay images from a VEGF assay.  Selected 
VEGF microspheres are circled in green, selected IL-8 microspheres are circled in red, 
and two false negative VEGF microspheres are circled in blue.   
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Figure 2.4.  Results of assays comparing eight different dynamic coatings and a silane 
coating.  The superior performance of PBS/PEG10k led to it being used for all future 
assays.  Error bars indicate the bead-to-bead variation within an array.   
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Figure 2.5.  Results of (A) secondary antibody and (B) cytokine incubation time 
optimization for VEGF.  Based on these results, a 15 min secondary antibody incubation 
and 20 min sample incubation time were used for all future assays.  Error bars indicate 
bead-to-bead variation within an array.   
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Figure 2.6.  Results of (A) secondary antibody and (B) AF488 concentration 
optimization for VEGF.  Based on these results, 3 μg/mL secondary antibody and 20 
μg/mL AF488 solutions were used for all future assays.  Error bars indicate bead-to-bead 
variation within an array.   
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Figure 2.7.  Results of the limit of detection determination for VEGF in buffer.  The 
theoretical limit of detection is 15 fM.  The limits of detection for VEGF in saliva 
supernatant as well as those for IL-8 in buffer and saliva supernatant are shown in table 
2.3.  Error bars indicate bead-to-bead variation within an array.   
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CHAPTER 3 
MICROFLUIDIC PCR CHIP INCORPORATING DNA EXTRACTION  
3.1 Introduction 
Many different microfluidic devices to perform PCR amplification have been 
developed.  The level of integration of the microfluidic device affects which substrate 
materials are used.  For example, if a capillary electrophoresis (CE) separation is to be 
integrated on-chip then the materials need to be CE compatible.  If optical detection will 
be used, than the chip materials, at least in the detection region, need to be optically 
transparent.  Materials, including silicon, glass, PDMS, polycarbonate, and other 
polymers have been reported, though some are better suited to PCR than others.
1, 2
  
Silicon has a high thermal conductivity that makes rapid thermocycling possible; 
however, its opacity limits detection options in a fully integrated system.
2, 3
  The optical 
transparency of glass makes highly sensitive fluorescence detection possible, and its 
electrical insulation properties allow coupling to a CE separation step for analysis of the 
PCR products.
2, 3
  However, both silicon and native glass surfaces can inhibit PCR.
2-4
  
Additionally, glass and silicon devices can be expensive to manufacture, often making 
disposable chips produced from these materials impractical.
3, 5-7
  Polymeric devices have  
consequently become more common.
6, 7
  PDMS chips are easily fabricated on a prototype 
scale, are optically transparent, and are more compatible with PCR than silicon or glass.
3, 
7
  Lower fabrication costs make PDMS chips readily disposable, reducing cross-
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contamination risks.
6
  Hybrid devices, containing two or more materials, are often used to 
exploit the benefits of one material and to offset the drawbacks of another.
8-11
   
The level of integration will also affect the degree of interaction a user has with 
the device.  For a true sample-in answer-out microfluidic device, the sample preparation 
and reagent delivery steps must be integrated onto the device.
5, 12-14
  For a PCR device, a 
critical step in the sample preparation is extracting DNA from the sample.
15, 16
  Many 
chip designs have been described that integrate sample preparation and PCR onto the 
same device.  Sample preparation steps usually include both cell lysis to release the DNA 
from the nucleus of the cell and DNA extraction to separate the DNA from sample 
components that may inhibit PCR.  Some chip designs only integrate cell lysis with PCR 
and perform amplification without the extraction step.
17-19
  This is sufficient for samples 
with no PCR inhibitors, but most clinical samples, including saliva, contain a wide 
variety of PCR inhibitors such as proteases and DNase and require an extraction step.
20
  
In another strategy, antibody-functionalized beads were used to capture target cells and 
separate them from the rest of the sample.
21
  Cell lysis was then performed in the PCR 
chamber without a DNA extraction step.  This may sufficiently remove PCR inhibitors 
for some samples, but analysis for more than one species would require antibody-
functionalized beads for each target, making the addition of new species difficult.  
Several chip designs have been described that use silica-based separations or magnetic 
beads for extraction.
22-26
  Silica and some magnetic beads are strong PCR inhibitors, so 
the DNA must be eluted before downstream amplification, often with ethanol, another 
strong PCR inhibitor.
15, 27-30
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Aluminum oxide membranes (AOMs) are an alternative to silica and magnetic 
beads for DNA extraction.  AOMs are rigid membranes made of a highly ordered 
alumina matrix with porosities of 25-50%.  They are commercially available with highly 
monodisperse pore sizes of either 20, 100, or 200 nm.  They have previously been used to 
extract -DNA, gDNA from lysed whole human blood samples, gDNA from lysed 
bacteria cells grown in culture, and viral DNA from cerebrospinal fluid samples.
27, 28, 31-34
  
Unlike silica-based DNA extractions, PCR of extracted DNA has been performed directly 
on AOMs with no need for an elution step.
27, 31, 33
  This is possible because PCR master 
mixes have a basic pH and are able to release the DNA bound to the membrane, freeing it 
for amplification.
28
  Polymerase will adsorb to the surface of the AOM, and so devices 
with large regions of exposed AOM may require the addition of BSA and additional Taq 
polymerase to the reaction mixture to minimize inhibition.
33
   
In this chapter the development of a microfluidic device to perform DNA 
extraction and PCR of bacterial DNA targets for POC diagnosis of respiratory infections 
is described.  The DNA extraction is performed with AOMs integrated into a 
PDMS/glass hybrid chip with polypropylene reservoirs to form PCR chambers.  Both the 
extraction and amplification steps were initially developed off-chip in PCR tubes and 
later integrated and tested on-chip with purified DNA.  The amplification step was first 
developed using -DNA and then bacterial gDNA.  Haemophilus influenzae, 
Staphylococcus aureus, Streptococcus mitis, Streptococcus mutans, Streptococcus 
pneumoniae, and Streptococcus salivarius were used as model organisms. 
The initial goal of this work was to multiplex the PCR and simultaneously test for 
many different organisms by using broad range primers.  Standard PCR primers are 
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specific to their intended target, so multiplexing with standard primers requires a unique 
primer set for each organism or gene.  Performing multiplex PCR with many sets of 
unique primers in the same reaction is difficult.  Overlapping primers can produce 
dimers, reducing target amplification, other non-specific interactions between primers 
can also prevent amplification, and incompatible cycling temperatures can result in 
amplification failure for one or more of the targets.
35, 36
  In contrast, broad-range PCR 
primers are for highly conserved sequences of DNA, usually in genes that encode for 
essential molecules.
37, 38
  The conserved sequences are the same across multiple species, 
but the amplicons include highly variable regions that can be used to identify bacterial 
species.
37, 39, 40
  The presence of target organisms can then be determined through DNA 
hybridization assays targeting these variable regions.   
Successful detection of the broad-range PCR amplicons was to be achieved using 
an array of oligonucleotide-functionalized microspheres similar to the array of antibody-
functionalized microspheres described in Chapter 2.  The Walt group has developed 
encoded microspheres functionalized with oligonucleotide probes that can be used to 
capture amplicons from PCR.
41-48
  The PCR products are hybridized to the 
oligonucleotide array and detected via fluorescence.  Biotinylated primers and AF488 can 
be used to take advantage of the biotin-streptavidin linkage for detection as in Chapter 2, 
or the primers can be directly labeled with fluorescent tags to generate labeled amplicons 
and decrease the complexity of the hybridization assay.   
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3.2 Materials and Methods 
Materials and Reagents 
PCR tubes (200 μL) were obtained from Eppendorf (Hauppauge, NY).  AOMs 
(13 mm diameter, 60 μm thickness, and 0.2 μm pores) were obtained from Whatman 
(Piscataway, NJ).  Luer Lok syringes (5 mL) were obtained from BD (Franklin Lakes, 
NJ).  O-rings (7/32” inner diameter, 11/32” outer diameter) were purchased from Parker 
Nitrile (Cleveland, OH).  Biopsy punches with 1 and 3 mm diameters were obtained from 
Miltex (York, PA) and Sklar Instruments (West Chester, PA), respectively.  Sylgard 184 
(PDMS) was obtained from Dow Corning (Midland, MI).  PDMS was prepared following 
the manufacturer’s recommendation with a 10:1 polymer to cross-linker ratio.  Silicon 
wafers were purchased from Silicon Quest International (San Jose, CA).  ELIMINase 
cleaner was obtained from Decon Labs, Inc. (King of Prussia, PA).  HotStarTaq 
polymerase, PCR buffer, and MgCl2 were purchased from Qiagen Sciences, Inc. 
(Germantown, MD).  dNTPs were purchased from Stratagene (Cedar Creek, TX).  
Purified -DNA was purchased from Promega (Madison, WI).  Red food coloring was 
purchased from Market Pantry, Target Corp. (Minneapolis, MN).  Purified gDNA from 
H. influenzae (ATCC 51907), S. aureus (ATCC 25923), S. mitis (ATCC 49456), 
S. mutans (ATCC 25175), S. pneumoniae (ATCC 33400), S. salivarius (ATCC 9759), 
Actinomyces naeslundii (ATCC 12104), Capnocytophaga gingivalis (ATCC 33624), 
Prevotella melaninogenica (ATCC 25845), and Veillonella parvula (ATCC 10790) was 
purchased from ATCC (Manassas, VA).  Custom primers for -DNA and bacterial 
targets, 20x RNase free Tris-EDTA (TE) buffer, streptavidin-Alexa Fluor 488 (AF488) 
conjugate, and a ULYSIS Alexa Fluor 488 nucleic acid labeling kit were purchased 
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from Invitrogen (Carlsbad, CA).  Purified gDNA and custom primers were resuspended 
following the instructions provided by their respective manufacturers.  Resistance 
temperature detectors (RTDs) with 100  resistance (F3102) were purchased from 
Omega Engineering, Inc. (Stamford, CT).  PEG with an average molecular weight of 
10,000 g/mol (PEG 10k) was obtained from Alfa Aesar (Ward Hill, MA).  DNase, 
RNase, and protease free water, PVP with an average molecular weight of 10,000 g/mol, 
saline sodium citrate (SSC) buffer (20x concentrate), and 20% sodium dodecyl sulfate 
solution (SDS) were purchased from Sigma-Aldrich (St. Louis, MO).  Microcentrifuge 
tubes (0.6 mL), sodium chloride (NaCl), glass cover slips (20 mm x 35 mm, 150 μm 
thick), isopropanol, Blocker BSA (10%) in PBS, DNase and RNase free mineral oil, 
Lyse-N-Go PCR reagent, PBS Starting Block blocking buffer, TBS Starting Block 
blocking buffer, and 1% (w/v) blocker casein in TBS were purchased from Thermo 
Fisher Scientific (Waltham, MA).  Unless otherwise noted, dilutions were performed 
using DNase, RNase, and protease free water.   
Tube-Mounted AOMs 
Tube-mounted AOMs were used for initial DNA extraction experiments.  They 
were made by cutting the bottom 2-3 mm off of a 200 μL PCR tube, heating an AOM on 
a hotplate to 185 °C, and then pressing the cut end of the PCR tube onto the AOM for 
10-20 s until they were hermetically bonded.  Excess AOM was trimmed away after 
bonding.  Each 13 mm AOM could be used to make 3 or 4 tube-mounted AOMs.  An 
image of a tube-mounted AOM is shown in figure 3.1.   
DNA extraction experiments were performed by filtering DNA solutions through 
tube-mounted AOMs.  An empty 5 mL syringe fitted with a suction cup was used to 
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apply pressure to the top of the tube-mounted AOM and push sample solutions through 
into a larger 0.6 mL microcentrifuge tube.  The DNA concentration of each solution was 
measured using a NanoDrop 2000 micro-volume UV/Vis Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) before and after filtration.  The default double-stranded 
DNA settings were used for measurements, reporting a nucleic acid concentration based 
on absorbance at 260 nm and the Beer-Lambert equation.  The average of three 
measurements was used to calculate the DNA concentration.  The amount of DNA 
captured on the AOM was calculated from the difference between the concentrations 
measured before and after filtration.   
Some samples were forced through the AOM using centrifugation or vacuum.  
For centrifuge filtration, the tube-mounted AOM was put into a 0.6 mL microcentrifuge 
tube, the sample solution was added, and the nested tubes were centrifuged for 5 min at 
900 rpm.  For vacuum filtration, an o-ring was fitted around the top rim of the tube-
mounted AOM and it was nested into a 0.6 mL microcentrifuge tube with an access hole 
in the side for applying vacuum.  After sample addition into the tube-mounted AOM, 
vacuum was applied to the microcentrifuge tube, filtering the sample through the AOM.   
The feasibility of preloading primers onto the AOM prior to DNA capture was 
tested using fluorescently labeled primers and a tube-mounted AOM.  The primers were 
labeled with a ULYSIS labeling kit according to the kit instructions.  The concentration 
of primers in solution after the labeling reaction was measured with the NanoDrop as 
before, but with the default settings for single-stranded DNA.   
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PCR Chip Design and Fabrication 
The microfluidic chip consisted of three main parts: wells to hold sample and 
PCR solutions, the AOM to extract DNA, and a microfluidic channel and AOM support 
structure for fluid flow through the AOM.  A variety of designs for the wells were tested.  
An image and schematic of the final design using sections of PCR tubes to form three 
reaction wells are shown in figure 3.2.  The microfluidic chip base was composed of a 
PDMS layer with a channel bonded to a 150 μm thick glass cover slip.  An 11 mm 
diameter region of microposts that supported the AOM for fluid flow was situated on the 
top of the PDMS layer.  A 1 mm biopsy punch was used to make a hole through this 
11 mm region and connect the micropost region to the fluidic channel underneath.  A thin 
layer of PDMS (~0.5 mm thick) containing three holes, each made with a 3 mm biopsy 
punch, was affixed over the AOM using uncured PDMS.  Sections of PCR tubes were 
also attached with uncured PDMS and positioned over the 3 mm holes atop the AOM to 
create the reaction wells.   
A double-sided molding strategy was used to make the microfluidic base of the 
chip.  To make the AOM supporting microposts, 15 arrays of approximately 75 μm 
diameter, 18 μm deep holes were etched into a silicon wafer using DRIE (Alcatel AMS 
100 DRIE) with a low-roughness Bosch process.  A secondary mold was cast in PDMS 
from this wafer and subsequently used to make a tertiary mold, also in PDMS, for chip 
manufacture.  The tertiary mold was necessary because one side of the double-sided mold 
must be flexible for demolding of the chips.  Another silicon wafer was etched to give 15 
channels that were 300 μm wide, 1.6 cm long, and 30 μm high.  Uncured PDMS 
(~10 mL) was spin-coated (Spincoater Model P6700, Specialty Coating Systems, Inc., 
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Indianapolis, IN) onto this wafer at 750 rpm for 1 min, degassed under vacuum, and 
cured for 5 min at 150 °C.  An additional 10 mL of uncured PDMS was spun onto the 
tertiary PDMS mold of the microposts at 550 rpm for 1 min and the micropost mold was 
mated to the PDMS layer on the silicon channel mold with the post regions aligned to the 
ends of the channels.  The PDMS layer in the mold sandwich was degassed under 
vacuum and then cured for 15 min at 150 °C.   
The casting was demolded, cut into individual chips with one channel and 
micropost region each, and excess PDMS was trimmed away.  To connect the post region 
to the fluidic channel, 1 mm holes were punched, and 3 mm access holes for the waste 
reservoirs were also punched.  The chips were washed on both sides with isopropanol and 
dried with N2 gas.  The glass cover slips were cleaned with ELIMINase and dried with N2 
gas prior to bonding.  The chip was bonded to the cover slip by exposing both to 
atmospheric plasma for 12 s at 18 W in a Harrick plasma cleaner (model PDC-32G, 
Pleasantville, NY) and then pressing the two together with the channel side of the chip 
facing down onto the glass.  After bonding, an AOM was placed over the micropost 
region.  The underside of an ~15 mm diameter circle of ~0.5 mm thick PDMS with three 
3 mm diameter holes was coated with a thin layer of uncured PDMS and placed over the 
AOM.  PCR tubes with the bottoms and tops trimmed off, making hollow conical 
cylinders 8-9 mm high, were used as reservoirs.  The larger ends of reservoirs were 
dipped in uncured PDMS and positioned over each of the holes in the PDMS layer above 
the AOM and above the waste access hole.  The cover slip-PDMS-AOM-PDMS-
reservoir sandwiches were heated to 95 °C for 15 min to cure the interstitial PDMS and 
complete chip fabrication.  Chips were stored dry and at room temperature.   
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PCR Development 
For on-chip DNA extraction, 20 μL of sample solution was added to each well 
and vacuum was applied to the waste reservoir until the entire sample had been pulled 
through the AOM, usually 5-10 min.  Then 10 μL of PCR master mix containing 1x PCR 
buffer, 5 units HotStarTaq DNA polymerase, 3.5 mM MgCl2, 200 μM of each dNTP, and 
0.75% Blocker BSA, as well as 0.4 μM of each primer was added to each well.  The PCR 
solution in each well and the waste reservoir was then covered with 25 μL of mineral oil.  
The master mix contained DNase, RNase, and protease free water dyed red with a small 
amount of food coloring to make the location and any evaporation of the PCR solution in 
the chip apparent.  The chip was thermocycled using an Eppendorf Mastercycler Personal 
(Eppendorf, Hauppauge, NY) benchtop thermocycler with an aluminum plate made in-
house to fit the thermocycler.  The heated lid was not used for on-chip PCR.  Prior to 
performing any on-chip PCR experiments, the temperature cycling of the aluminum plate 
was monitored with an RTD to verify that the thermocycling temperature profile.  An 
image of the plate and a plot of a few temperature cycles are shown in figure 3.3.  The 
thermocycling program used for on-chip experiments with bacterial gDNA was 15 min at 
95 °C, 30 cycles of 45 s at 94 °C, 45 s at 56 °C, and 45 s at 72 °C, with a final extension 
step of 10 min at 72 °C.  The PCR products were collected after thermocycling and stored 
in clean PCR tubes at 4 °C until analysis using an Agilent 2100 Bioanalyzer with DNA 
1000 kits (Santa Clara, CA).  The Bioanalyzer performs capillary gel electrophoretic 
separations of the PCR products to determine the size and concentration of the amplicons 
for up to twelve samples.  PCR chips were discarded after thermocycling, and a new chip 
was used for each experiment.   
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PCR in tubes was performed using the Eppendorf thermocycler with the heated 
lid set to 105 °C.  For bacterial gDNA experiments, the master mix and thermocycling 
program described above were used.  For PCR of -DNA, the master mix consisted of 1x 
PCR buffer, 2.5 units HotStarTaq DNA polymerase, 2.0 mM MgCl2, and 200 μM of each 
dNTP, as well as 0.2 μM of each primer.  The thermocycling program was 15 min at 
95 °C, 30 cycles of 30 s at 95 °C, 30 s at 54 °C, and 45 s at 72 °C, with a final extension 
step of 10 min at 72 °C.  These PCR products were also analyzed with the Bioanalyzer.   
-DNA was used for initial PCR development.  Primers for a 294 bp region were 
designed using the OligoPerfect tool on the Invitrogen website and the -DNA 
sequence obtained from NCBI’s GenBank (accession number J02459.1).  Six species of 
bacteria were used as model organisms for PCR development.  H. influenzae, S. aureus, 
and S. pneumoniae are all pathogenic bacteria while S. mitis, S. mutans, and S. salivarius 
are control organisms commonly found in the human mouth.  Broad-range primers 
described by Roth, et. al., for an ~300 bp region of the gyrB gene that encodes for DNA 
gyrase, a protein that introduces negative supercoils in DNA, were used with bacterial 
gDNA.
37
  The gyrB gene is highly conserved in the regions the primers are designed for, 
while more variable regions are found between the primers.  Sequences for the -DNA 
and gyrB primers are listed in Table 3.1.   
Microarray Hybridization Assays 
Hybridization assays were performed with oligonucleotide probe-functionalized 
microspheres provided by the Walt group at Tufts University.  A schematic of the 
microsphere-based hybridization assay is shown in figure 3.4 and the primer and probe 
sequences are listed in table 3.2.  Chips similar to those developed for protein assays in 
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Chapter 2 were used.  The microspheres average 4.5 μm in diameter so microarrays with 
6 mm diameter wells were used to accommodate the larger beads.  Chips were loaded 
with beads in the same manner described in Chapter 2, using PBS buffer with 0.1% 
PEG 10k.  The probes on the beads targeted four model control organisms: 
P. melaninogenica, C. gingivalis, A. naeslundii, and V. parvula.  The primers designed by 
the Walt group were biotinylated so that PCR products could be readily detected in the 
oligonucleotide array after reacting with fluorescently labeled streptavidin.  The 
biotinylated amplicons hybridize to probes on the microspheres and a stringency wash 
removes nonspecifically bound DNA.  Then AF488 forms a linkage with the biotin 
during a staining step.  A final wash removes excess AF488, and the amplicons 
hybridized to the microspheres can be detected.  PCR products for hybridization assays 
were generated with 50 μL tube-based PCR with 1 ng of purified gDNA as the template, 
1x PCR buffer, 2.5 units HotStarTaq DNA polymerase, 1.5 mM MgCl2, 200 μM of each 
dNTP, and 0.2 μM each of the appropriate forward and reverse primers with the 
following thermocycling program: 15 min at 95 °C, 35 cycles of 30 s at 95 °C, 30 s at 
55 °C, and 30 s at 72 °C, with a final extension step of 10 min at 72 °C.   
The Walt group hybridization assay protocol was adapted for use on a 
microfluidic chip.  The PCR products were first denatured by incubating for 5 min at 
95 °C and then chilled on ice for 1 min.  All other steps in the hybridization assay were 
performed at room temperature.  The denatured products were delivered to the bead 
arrays and incubated for 30 min.  The arrays were next rinsed with the stringency wash 
solution (2x SSC, 0.2% SDS) for 2 min and then the general wash solution (0.5x SSC) 
for 1 min.  The arrays were then incubated with blocking solution (1% blocker casein in 
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TBS) for 5 min followed by staining solution (2 μg/mL AF488 in blocker casein) for 
10 min.  The array was then rinsed with the general wash solution again for 1 min, dried 
with vacuum, and imaged using the same microscope setup, filters, and exposure times as 
described for the protein microarrays.  The images were also analyzed in the same way.   
3.3 Results and Discussion 
DNA Extraction 
DNA extraction by AOM was investigated using tube-mounted AOMs.  Solutions 
of three different concentrations of -DNA (80 μg/mL, 40 μg/mL, and 20 μg/mL) were 
filtered through tube-mounted AOMs using pressure from a syringe.  The sample size 
was 25 μL.  Three replicates were performed at each concentration, as well as three 
blanks using water.  The concentration of -DNA in the solutions before and after 
filtration through the AOM was measured, and the difference was used to calculate the 
amount of DNA captured.  A greater percentage of DNA was captured from the samples 
with lower concentrations, but the total DNA captured at all three concentrations was 
similar (table 3.3).  This suggests that the amounts of DNA used in this experiment 
exceeded the maximum amount of DNA that could be captured by the tube-mounted 
AOMs under these conditions.  Due to variations in the fabrication, the exposed area of 
AOM will be slightly different for each AOM.  This is likely the reason for deviations in 
the total amount of DNA captured.   
Another experiment investigated the effect of the method used to effect fluid flow 
through the AOM on the amount of DNA captured.  On a microfluidic chip, vacuum will 
be used to pull solutions through the AOM, so experiments using either a centrifuge or 
vacuum were undertaken.  These techniques are more complex than the syringe method, 
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but it was important to verify that results from experiments with the syringe method 
would still be applicable to on-chip DNA extraction.  Sample solutions of 40 μg/mL 
-DNA (25 μL each) were filtered through each AOM.  Centrifugation was compared to 
the syringe method on one day and vacuum was compared to the syringe method on a 
second day.  On each day, three replicates were performed for each filtration technique as 
well as three blanks.  On the first day centrifugation was used with the blanks while on 
the second day the syringe method was used.   
The results of these experiments are shown in table 3.4.  Similar amounts of DNA 
were captured with the vacuum filtration method as with the syringe method, with no 
discernable difference observed between using the vacuum or the syringe.  With a 10% 
greater percentage of DNA captured, the syringe method was found to be slightly better 
than using the centrifuge.  It is unclear why there was a decrease in the amount of DNA 
captured for the centrifuge method.  One possibility is that the forces in the centrifuge 
caused small cracks in the AOMs, allowing solutions to pass through the cracks instead 
of through the pores, therefore reducing the amount of DNA captured.  There is also a 
great difference between the amounts of DNA captured with the syringe method between 
the two days.  This may be due to the AOMs used on the first day (comparing syringe 
with centrifuge) being fabricated with a larger area of AOM exposed for filtration, day-
to-day variations with the NanoDrop, or DNase contamination on the first day resulting 
in lower post-filtration DNA concentrations measured by the NanoDrop.   
Kim and Gale have also described DNA extraction with AOMs and found that the 
amount of DNA captured increased with increasing NaCl concentration.
28
  This effect 
was confirmed by performing a DNA capture experiment with 25 μL samples of 20 
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μg/mL -DNA solutions containing 0 mM, 100 mM, 300 mM, or 500 mM NaCl.  Three 
replicates were performed at each concentration along with three blanks containing no 
DNA and 0 mM NaCl.  The syringe method was used to filter solutions through the 
AOM.  The results are shown in table 3.5.  There was 100% DNA capture from the 
solutions containing additional NaCl while only 31% of the DNA was captured from the 
0 mM solution.  The 0 mM solution is the same as the 20 μg/mL -DNA solution used in 
the first DNA capture experiment described and as expected the results are similar, 
although lower.  These results agree with those found by Kim and Gale who offered two 
explanations for the increase.
28
  In high salt conditions the DNA may be able to form a 
salt bridge with the AOM, which would increase binding.  The salt may also neutralize 
the charge on the DNA eventually resulting in DNA aggregation to the point that the 
aggregates may not be able to pass through the pores in the AOM.  Kim and Gale thought 
the second explanation had a greater effect with membranes that have smaller pore 
diameters than the size used for this work.  No matter which mechanism is behind the 
increased DNA capture, adding NaCl to samples can be used to improve DNA extraction 
efficiency if necessary for later experiments.  Just 1 ng of DNA is often more than 
enough for successful PCR, and that amount is easily captured without adding NaCl to 
the sample solution.  However, if the target DNA is a very small percentage of the total 
DNA in solution, NaCl could be added to capture enough total DNA to get a sufficient 
amount of target DNA for PCR.   
The effect of buffer concentration was also investigated by performing a DNA 
capture experiment using -DNA samples with different buffer concentrations.  The 
concentrated -DNA is supplied in TE buffer, but the sample solutions prior to this 
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experiment were diluted only with water.  For this experiment the sample solutions all 
contained 20 μg/mL -DNA in either 0 mM, 10 mM, 50 mM, or 150 mM additional TE 
buffer.  Three replicates were performed at each concentration along with three blanks 
containing no DNA and 0 mM additional buffer.  The syringe method was used to filter 
solutions through the AOM.  The results are shown in table 3.6.  With the exception of 
the 10 mM samples, the results showed a decreasing amount of DNA captured with 
increasing buffer concentration, the opposite effect seen from increasing NaCl 
concentration.  For unknown reasons, repeated NanoDrop measurements for the 10 mM 
samples found a greater amount of DNA after filtration through the AOM than before, 
resulting in negative values for the amount of DNA captured.  The background 
measurements for those samples, taken with a solution containing 10 mM additional TE 
buffer but no DNA, were lower than usual, resulting in the apparent increase in DNA 
after filtration.  This may be a poor buffer for use with the NanoDrop, or there may have 
been some problem with this background solution causing the lower absorbance.  The 
experiment was not repeated since the trend in the rest of the samples indicated that 
increasing the TE buffer concentration did not facilitate DNA capture.  Kim and Gale 
found that cationic buffers are the best elution buffers to release DNA from AOMs,
28
 
which, since Tris buffers are cationic, would explain the poor DNA extraction with 
increasing concentrations of buffer.  If the DNA is easily dissolved in the buffer, it may 
not bind to the surface of the AOM.  For future experiments, dilutions of DNA for sample 
solutions continued to be made with only water.   
 
 
 71
Primer Spotting on AOMs 
With the success of DNA capture experiments, the potential to preload primers 
for PCR on the AOM was also investigated.  For the POC application, the same sample 
will be used for all reaction wells on a chip but there would be different primer sets in 
each well.  This would lower the level of multiplexing required of the reaction in each 
well.  Since all the PCR reagents other than the primers are identical for all wells, a way 
to store the primers on-chip in the appropriate wells would simplify chip operation for the 
end user.  For this experiment gyrB primers were labeled with Alexa Fluor 488 using a 
ULYSIS labeling kit.  First, a tube-mounted AOM was imaged with a fluorescence 
microscope to obtain a background image (figure 3.5A).  Next, 10 pmol of primers were 
spotted onto the AOM and allowed to dry.  The AOM was then imaged again (figure 
3.5B).  The AOM was finally washed with 25 μL of water and imaged a final time (figure 
3.5C).  All of the images were taken with a 4 s exposure.  The regions of different 
fluorescence intensity seen in figure 3.5B are due to the majority of the primer solution 
being delivered to one side of the AOM.  As seen in the images, the fluorescence present 
after primer spotting does not disappear after the AOM is washed.  The primers remain 
on the AOM so pre-spotting different primers to reaction wells at the point of 
manufacturing appears feasible.   
PCR of Captured DNA 
With the success of the DNA extraction and primer spotting experiments, the next 
step was to determine if the DNA captured by the AOM could be amplified by PCR.  
First, 25 μL samples of a 40 μg/mL solution of -DNA (1 μg of DNA in each sample) 
were filtered through each of six tube-mounted AOMs using the syringe method.  Three 
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tube-mounted AOMs were run as blanks with DNase, RNase, and protease free water 
used in place of the -DNA.  After DNA capture, the dry AOMs were punched out into 
clean 200 μL PCR tubes using 1000 μL pipette tips.  PCR master mix (as described 
above for PCR of -DNA in tubes), including forward and reverse primers for a 294 bp 
region of -DNA, was added to each tube to a total volume of 50 μL.  The reactions were 
then thermocycled with the temperature program described above for -DNA in tubes.  
Two positive controls, each containing 5 ng of -DNA added in solution, and one 
negative control that did not contain AOM were thermocycled alongside the other 
reactions.  After PCR, the solutions were analyzed on the Bioanalyzer to determine if 
successful PCR amplification occurred.  Figure 3.6 shows a gel representation of the 
Bioanalyzer results for this experiment.  The bands at ~300 bp indicate product was 
present in those samples.  Amplification was successful for all tubes containing DNA, 
and no amplification was seen for any of the blanks.  Since the experiment was successful 
for DNA captured on the AOMs, DNA extracted with AOMs can be used for PCR 
without any need for a separate elution step.   
Pre-spotting primers for amplification of DNA captured on the AOM was then 
tested.  Nine tube-mounted AOMs were spotted with 30 pmol each of forward and 
reverse -DNA primers (~3x the amount of primers used in the previous 50 μL PCR 
reactions to allow for some loss of primers during the DNA extraction step).  DNA 
extraction was performed using the syringe method with 25 μL of a 20 μg/mL -DNA 
solution (500 ng of DNA in each tube).  The previous experiment was performed before 
determining that 40 μg/mL solutions of -DNA contain more DNA than can be captured 
on a tube-mounted AOM.  In this experiment, the concentration of -DNA was decreased 
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to the lowest concentration tested for DNA capture.  After extraction, the AOMs were 
punched out into clean PCR tubes and PCR master mix without primers was added to 
each tube to a final volume of 50 μL.  One negative and two positive controls were 
included as described for the previous experiment with -DNA and primers added in 
solution (10 pmol each of forward and reverse primers).  The reactions were then 
thermocycled and the products analyzed on the Bioanalyzer.  The results are shown in 
figure 3.7.  Amplification was successful for all wells except the blanks, so the primers 
can be loaded onto the AOM before DNA extraction and will still be available to amplify 
the target DNA.   
Initial Development of a PCR Chip 
After successful amplification of DNA captured with tube-mounted AOMs, 
integration of the AOM onto a microfluidic PCR chip was explored.  Initial chip designs 
were similar to that shown in figure 3.2 but without the micropost region to support the 
AOM.  Instead, access holes at both ends of the microfluidic channel were made with a 3 
mm punch and a reservoir was placed above the hole at one end to make a single reaction 
well.  The first reservoirs tested were made out of PDMS and could contain a 50 μL PCR 
reaction overlaid with 50 μL of mineral oil.  An image of one of these chips is shown in 
figure 3.8A.  This reaction well design had a tendency to leak and PCR with these chips 
was not successful.  Another reservoir design used a solid block of PDMS (~7.5 mm 
thick) molded with the lower channel layer to ensure that the reservoirs would be 
completely sealed.  An image of one of these chips is shown in figure 3.8B.  This design 
did eliminate the leaking problem, but PCR was not successful, possibly due to the 
thermal mass of the PDMS preventing accurate thermocycling.  Eventually, the reservoir 
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design using sections of PCR tubes described in section 3.2 was tested.  The reaction 
volume (10 μL) was smaller than before, and although leaking and evaporation were no 
longer problems, PCR was still not successful.   
In addition to evaluating different reservoir designs, larger access holes were also 
tested to expose more of the AOM surface.  With the larger holes, the AOM had a 
tendency to flex downward and touch the glass surface when vacuum was applied.  This 
sealed the channel and prevented fluid flow.  The AOM’s brittleness and its flexing under 
vacuum occasionally resulted in cracking.  The micropost region was developed to allow 
access to a greater AOM surface area while still providing support to prevent flexing 
under vacuum.  The microposts also increased flexibility in reservoir placement and 
allowed multiple reaction reservoirs on the same chip.  Without the microposts, the 
reaction reservoir had to be located directly above the channel access hole.  If the 
reservoir was misaligned, solutions could not be transported through the AOM.  With the 
microposts, multiple reservoirs can be located throughout the micropost region and still 
allow solutions to be filtered through the membrane.  The microposts also make it 
possible to reduce the diameter of the access hole at the end of the channel under the 
membrane to 1 mm, reducing the dead volume beneath the AOM.   
PCR Inhibition from AOMs 
After on-chip PCR failure for multiple reservoir designs, an investigation of on-
chip conditions was undertaken to achieve successful amplification.  A major difference 
between PCR in tubes and on-chip is the surfaces the solution is in contact with.  Many 
materials used to make microfluidic devices will inhibit PCR.
4
  While the PCR tubes 
used to make the reservoirs do not inhibit PCR, the solutions are also in contact with 
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PDMS and the AOM.  PDMS is not known to be a major PCR inhibitor
4
 and this was 
confirmed by performing PCR in tubes with pieces of PDMS.  Although the previous 
experiments with tube-mounted AOMs did not indicate that AOMs would inhibit PCR, 
the amount of AOM in those experiments was very small relative to the reaction volume.  
A much larger surface area was exposed on-chip and the reaction volume was decreased 
to 10 μL.  Therefore, the surface area-to-volume ratio was much greater on-chip.  Since 
the degree of PCR inhibition is positively correlated to surface area-to-volume ratio,
4
 the 
effect of a larger area of AOM was investigated.   
Different amounts of AOM were placed into PCR tubes.  The mass of AOM 
added to each tube was assumed to correlate to exposed surface area.  PCR in these tubes 
was performed with either 5 or 25 ng of -DNA template in a 50 μL reaction volume.  
The reactions were thermocycled and the products were analyzed with the Bioanalyzer.  
A plot of PCR product concentration vs. mass of AOM added to the reaction is shown in 
figure 3.9.  The concentration of PCR products decreased as the amount of AOM 
increased, confirming that the AOM inhibits PCR when the surface area-to-volume ratio 
is large.  Inhibition from the AOM was probably not the cause of PCR failure for the 
initial reservoir designs since they used 50 μL reaction volumes and the surface area of 
the exposed AOM would correlate to ~0.25-1 mg.  Failure in those designs was probably 
due to the leakage problems and inaccurate thermocycling temperatures.  However, 
inhibition from the AOM was most likely the cause of failure for the chip designs with 
greater than 3 mm diameter access holes and for the initial test of the final reservoir 
design with a 10 μL reaction volume. 
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PCR inhibitors generally cause one or more of three possible problems with a 
reaction: they interfere with cell lysis and the release of template DNA, they degrade or 
otherwise make nucleic acids unavailable, or they inhibit polymerase activity.
20
  The 
previous failed reactions used purified DNA, so cell lysis was not an issue, and figure 3.9 
shows that the initial amount of template had no noticeable effect on product 
concentration.  Inhibition of polymerase activity was therefore evaluated as the 
mechanism for PCR failure, since the AOM could bind Taq polymerase.  Adding 
additional polymerase to the reaction is one possible solution, but Taq polymerase is one 
of the most expensive reagents used for PCR.  Another possible solution is to add a 
blocking agent, like BSA, to the master mix to prevent adsorption.  Both of these 
solutions were tested.  PCR was performed with 5 ng of -DNA, a 50 μL reaction 
volume, and 4-5 mg of AOM added to each tube except for two positive controls 
containing no AOM.  Qiagen recommends 2.5 units of Taq polymerase per reaction, and 
this was the amount used for previous experiments.  Adding up to 2.5 additional units, in 
0.5 unit increments, was tested with duplicates at each concentration.  Adding BSA to a 
final concentration of 1% without additional polymerase was also tested.  A plot of PCR 
product concentration vs. Taq polymerase concentration is shown in figure 3.10.  
Increasing the amount of Taq led to small increases in product concentration, while the 
addition of BSA led to product concentrations much closer to that of the controls.  This 
confirms that the AOM was inhibiting the activity of the polymerase, and that a blocking 
agent added to the master mix can reduce the inhibition.   
While PCR in the presence of AOM with 1% BSA resulted in product 
concentrations similar to those of the controls, the high BSA concentration led to gelation 
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of the solutions upon heating.  Gelation would likely clog a microfluidic chip, preventing 
downstream analysis of the PCR products.  Duplicate reactions were performed to test six 
other potential blocking agents: Lyse-N-Go (a PCR compatible lysis reagent), 1% PEG 
10k, 1% PVP, 0.75% BSA, PBS Starting Block, and TBS Starting Block.  The results are 
shown in figure 3.11A.  While none of the blocking agents worked as well as 1% BSA, 
acceptable results without gelation were obtained with 0.75% BSA, PBS Starting Block, 
TBS Starting Block, and Lyse-N-Go.   
In a POC device with saliva samples, other factors can negatively affect PCR 
efficiency, such as PCR inhibitors from the sample.  While the blocking agents produced 
acceptable results under the nearly ideal conditions in tubes, eliminating as much of the 
effect of the AOM as possible will reduce the chances of PCR failing on the POC device.  
Lyse-N-Go, 0.75% BSA, and PBS Starting Block were tested with additional Taq 
polymerase, with 2.5, 4.0, and 5.0 total units of Taq polymerase per reaction.  Duplicate 
reactions were performed for each blocking buffer at each concentration of Taq 
polymerase.  These results are shown in figure 3.11B.  The reactions with 0.75% BSA 
and 5.0 units of Taq polymerase had a product concentration closest to that of the 
controls, so these conditions were used to prevent inhibition from the AOM in future on-
chip PCR experiments.   
On-Chip DNA Extraction and PCR 
With the addition of 0.75% BSA to the master mix to prevent polymerase 
adsorption to the AOM, on-chip PCR with 10 μL reaction volumes was retested.  The test 
was performed with gyrB primers and bacterial gDNA from S. pneumoniae and 
S. aureus.  Master mix and template DNA in solution were pipetted into the reaction 
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wells and then overlaid with mineral oil.  Mineral oil was also added to the waste 
reservoir to prevent evaporation through the waste channel.  Three chips with three 
reaction wells each were thermocycled.  One chip contained 1 ng of S. pneumoniae 
gDNA as the template in each well, one chip contained 1 ng of S. aureus gDNA in each 
well, and the final chip was a blank with no template in any of the wells.  Three control 
reactions, a positive control for each target and one negative control, were run in PCR 
tubes.  The products were analyzed using the Bioanalyzer, and the results are shown in 
figure 3.12.  On-chip PCR was successful for both S. pneumoniae and S. aureus gDNA.  
This was repeated with gDNA from the other species of bacteria.  The results from H. 
influenzae and S. salivarius are shown in figure 3.13 and the results from S. mutans and 
S. mitis are shown in figure 3.14.  While the H. influenzae and S. salivarius samples 
worked as well as S. pneumoniae and S. aureus, only very small amounts of product were 
seen from S. mutans, and no product was seen in the S. mitis samples.  The S. mitis 
positive control also did not work as well as the other positive controls, indicating that 
even under ideal conditions, PCR efficiency for S. mitis was decreased.  Although 
optimization might have improved results for S. mitis and S. mutans, it was not 
performed, and they were dropped from the group of target organisms.   
PCR with preloaded primers and DNA capture was then evaluated on-chip.  As 
with the tube-mounted AOM primer spotting experiment, 30 pmol each of the forward 
and reverse primers, triple the usual amounts, was preloaded onto the AOM at the bottom 
of each reaction well.  Solutions of gDNA with concentrations of 50 ng/mL were made 
for each of the four remaining target organisms.  Samples of 20 μL were added to each 
well and filtered through the AOM, then 10 μL of master mix and 25 L of mineral oil 
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were added to each well, and the chip was thermocycled.  Control reactions, with primers 
and DNA added in solution, were performed in PCR tubes.  The results for S. 
pneumoniae and S. aureus are shown in figure 3.15 and the results for H. influenzae and 
S. salivarius are shown in figure 3.16.  Successful amplification was seen for all of the 
species, but the results for S. aureus were both the most consistent and had the greatest 
amount of product.  For the other species, there are one or more wells for which only a 
small amount of product was detected.  While some additional optimization of the on-
chip PCR is needed, the chip was successfully used to extract bacterial gDNA from a 
sample and amplify the target with PCR.   
Microarray Hybridization Assay 
Since the amplicons from the gyrB primers are approximately the same size (~300 
bp) for all of the bacterial targets, the Bioanalyzer cannot be used to determine the 
success of multiplexed PCR experiments.  Hybridization assays using a microarray of 
oligonucleotide-functionalized beads can be used instead, with a different bead type for 
each product.  The Walt group at Tufts University supplied oligonucleotide-
functionalized microspheres, but was not able to test probes and produce beads for the 
gyrB amplicons.  As an alternative, beads with probes for P. melaninogenica, 
C. gingivalis, A. naeslundii, and V. parvula were used to test an on-chip hybridization 
assay.  The Walt group designed a separate primer set for each of these organisms that 
could be multiplexed in a single reaction.  PCR with biotinylated primers for each of the 
four organisms was performed with bacterial gDNA in tubes with 50 μL reaction 
volumes to generate amplicons to use as samples for the hybridization assays.  Results of 
the Bioanalyzer analysis of products from PCR with multiplexed primers, including two 
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reactions with simultaneous amplification of both P. melaninogenica and V. parvula, are 
shown in figure 3.17.  In the reactions with two types of template DNA, the concentration 
of P. melaninogenica products is decreased due to competition with V. parvula.  Because 
of the effects of PCR competition, the hybridization assays were tested with products 
from reactions with only one set of primers and one type of template DNA.   
An initial hybridization assay test with three bead types and their matching PCR 
products was performed following the adapted Walt group protocol.  The arrays were 
imaged with an EMCCD on an epifluorescence microscope with 8 s exposures.  The 
results of the assay are shown in table 3.7.  S/N values were low because raw signals 
from the target beads were low and the signal from the control beads was very close to 
the signal from the target beads.  The S/N for C. gingivalis was lower than that for the 
blank, although the values are not completely comparable since the signal from the blank 
was measured off of the V. parvula beads.  The S/N for V. parvula was approximately 
double that of the blank, less than expected for such a concentrated sample.  The S/N for 
P. melaninogenica was the greatest, which was unexpected since its sample concentration 
was the lowest.  Optimization would most likely improve the signal from the target 
beads, and non-specific binding probably caused the relatively high control bead signal.  
The casein used as the blocking solution to prevent the dye from adsorbing to the channel 
and array surfaces is known to contain variable amounts of biotin.  Since the assay takes 
advantage of biotin-streptavidin binding to label the biotinylated PCR products with a 
streptavidin conjugated fluorescent dye, surfaces coated with biotin from the blocking 
step will be labeled with AF488 during the staining step.   
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An experiment was performed to compare three other blocking solutions, 1% 
BSA in PBS, PBS SuperBlock blocking buffer, and TBS Starting Block blocking buffer, 
with casein.  The blocking solutions were also used to make the AF488 staining 
solutions.  The assays were performed with the same protocol used in the previous 
experiment.  The results of the assays are shown in table 3.8.  For all of the blocking 
buffers tested, the result from the blank array was indistinguishable from the arrays 
incubated with PCR products.  This may indicate that there are additional problems with 
the assay other than non-specific binding.  Low signal from the target beads, probably 
due to poor hybridization, is the other possible reason for the S/N being the same for the 
blanks and the positive arrays.  Assay optimization could probably improve the signal, 
most likely by increasing the 30 min hybridization step in which the array is incubated 
with denatured PCR products to a longer duration.  Hybridization assays are commonly 
performed with long incubations, from 5 hrs to overnight.
37, 48, 49
  Shorter incubations 
have been successfully used, from 1 hr to less than 15 min,
41, 44, 50
 but do not seem to 
work with this particular array design and probe set.  Since the thermocycling for on-chip 
PCR already takes ~2 hrs and the hybridization assay takes ~1 hr, increasing the length of 
the hybridization step is undesirable if the assay time is to be kept within reasonable 
limits.  In the interest of minimizing the total PCR assay time, real-time PCR detection 
was pursued as an alternative to hybridization assays.   
3.4 Conclusions 
We have developed a microfluidic chip to extract DNA from samples and perform 
PCR of the extracted DNA.  By using a PCR-compatible AOM for DNA extraction, we 
integrated an important sample preparation step onto the chip without requiring complex 
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architecture to move DNA from a sample preparation region to an amplification region.  
The extraction procedure is very fast and is exceedingly simple, only requiring sample 
addition followed by filtration through the AOM.  Unlike other DNA extraction 
procedures, no centrifugation or washing steps are required.  This is considerably faster 
than other methods, including commercial kits, which, even with an elution step, can 
sometimes result in downstream inhibition of PCR.
51
  This uncomplicated extraction 
procedure means that on-chip DNA extraction could be fully automated with a reader 
device capable of reagent dispensing.  Primers can also be preloaded on the AOM before 
DNA extraction and used for PCR amplification.  Primer spotting helps make automation 
possible by allowing the same reagents to be dispensed onto a specific chip regardless of 
the target organisms.  Since the template DNA is extracted from the sample and the 
primers are preloaded onto the chip, only a single reagent solution (PCR master mix) 
needs to be delivered, irrespective of the bacterial targets.   
We found that higher NaCl concentrations and lower TE buffer concentrations 
increase the amount of DNA captured on the AOM.  The effect of other salts and buffers, 
and the effect of pH on DNA extraction were not investigated.  If greater extraction 
efficiency is needed for samples in the future, other sample additives and buffers could be 
explored.  We also did not extensively investigate the release of DNA from the AOM.  
Previous work has found that cationic buffers and a basic pH, like PCR buffer, will 
release DNA from the membrane.
28
  Since no problems with DNA release were observed 
in these experiments, DNA elution was not examined.  While the AOM worked well for 
DNA capture, at large surface area-to-volume ratios it was found to inhibit PCR through 
adsorption of the Taq polymerase.  The addition of 0.75% BSA and extra polymerase to 
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the master mix reduced the inhibition effects to the point where PCR amplification was 
possible.  The inhibition could be further reduced by using 1% BSA, but gelation of those 
solutions during thermocycling was incompatible with a chip design requiring 
downstream analysis of the PCR products.   
The microfluidic chip was made out of PDMS and polypropylene PCR tubes.  
The chips were made with PDMS because of its ease of laboratory-scale fabrication as 
well as its ability to seal the AOM and PCR tube reservoirs onto the chip.  The micropost 
design incorporated onto the chip was a major improvement since the number of 
reservoirs could be expanded while still using a single, unbranched channel for fluid 
flow.  A microfluidic device incorporating an AOM for DNA extraction has been 
previously described in the literature, but consisted of only one reaction chamber rather 
than the three in our design.  Although in these experiments all three reaction wells used 
the same primers, targeting multiple analytes by preloading different primers is possible 
and is described in Chapter 4 of this work.  Successful PCR of bacterial gDNA extracted 
onto the membrane, including primer spotting before DNA capture, was demonstrated on 
this device with gDNA from 5 species of bacteria.   
Currently the PCR products are detected off-chip using the Bioanalyzer.  An on-
chip detection scheme using oligonucleotide-functionalized microspheres was tested, but 
the results were disappointing.  The S/N values for assays with large amounts of PCR 
products were indistinguishable from blank assays with samples containing no PCR 
products.  Optimization of the assay, in particular increasing the length of the 
hybridization step, could probably improve these results, but optimization was not 
performed.  The hybridization assay tested already added an hour onto the 2 hr assay time 
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from DNA extraction and PCR.  Since the purpose is to develop a POC device, real-time 
PCR, described in Chapter 4, was pursued as the detection strategy in place of the 
hybridization assay.   
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3.5 Tables and Figures 
Table 3.1.  Primer sequences for -DNA and gyrB targets.  Sequences for gyrB were 
designed by Roth, et al.
37
   
Organism/gene Sequence 
-DNA 294 bp product 
forward 5-GGATTTAGTGCGCTTTCTAC-3 
reverse 5-GTGTGTGATACGAAACGAAG-3 
Bacterial gyrB ~300 bp product 
forward 5-CGTCCWGGKATGTAYATHGG-3 
reverse 5-CCHACRCCRTGWAAWCCDCC-3 
 
 
 
Table 3.2.  Primer and probe sequences for control organisms used with the hybridization 
array.  Biotin is attached to the 5 ends of reverse primers and probes with a C6 spacer 
arm.  Sequences were designed by the Walt group at Tufts University.   
Organism Sequence 
A. naeslundii 264 bp product 
forward 5-ATGAGACCAACCCCGACATC-3 
reverse 5-/Biotin/TGTAGTAGGAGAAGGAGACGAAG-3 
probe 5-/Biotin/CGCCAACTACGCCTTCGGAGACCTC-3 
C. gingivalis 227 bp product 
forward 5-AGAGTTTGATCCTGGCTCAG-3 
reverse 5-/Biotin/GGACGCATGCCCATCCTTTCACCACCGC-3 
probe 5-/Biotin/GCGTATGCAACCTACCTTTCACA-3 
P. melaninogenica 281 bp product 
forward 5-TCTGGAGAGGATGCTTATTAGTTG-3 
reverse 5-/Biotin/CAGTCTTGCTTGTGTCAATATGTC-3 
probe 5-/Biotin/CCTTATCCTCCACCACTGCTGTTCTATGCT-3 
V. parvula 232 bp product 
forward 5-CTGTAGATAATGGCGAATACTATGAAG-3 
reverse 5-/Biotin/CCAGGCAAGAAACCAGGAAC-3 
probe 5-/Biotin/GCTGGTTGCTTGGACATTAACGCTTCTGA-3 
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Table 3.3.  Effect of -DNA concentration on the amount of DNA captured with a tube-
mounted AOM.   
Sample Captured DNA (ng) % DNA Captured 
Blank -2.5 ± 10 - 
20 μg/mL 200 ± 47 53 ± 12 
40 μg/mL 120 ± 14 18 ± 1.9 
80 μg/mL 140 ± 21 8.5 ± 1.2 
 
 
 
 
Table 3.4.  Effect of the method used to move solutions through the AOM on the amount 
of DNA captured.  Sample solutions contained 40 μg/mL -DNA.   
Method Captured DNA (ng) % DNA Captured 
Blanks (day 1) 7.9 ±0.6 - 
Syringe (day 1) 260 ± 41 31 ± 5.0 
Centrifuge (day 1) 170 ± 27 20 ± 3.3 
Blanks (day 2) -9.7 ±10 - 
Syringe (day 2) 92 ± 27 13 ± 4.0 
Vacuum (day 2) 110 ± 14 17 ± 2.0 
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Table 3.5.  Effect of NaCl concentration on DNA capture with tube-mounted AOMs.  
Sample solutions contained 20 μg/mL -DNA.   
Concentration 
of NaCl 
Captured DNA (ng) % DNA Captured 
Blanks -51 ± 67 - 
0 mM 110 ± 4.6 31 ± 1.3 
100 mM 320 ± 4.9 110 ± 1.6 
300 mM 280 ± 31 100 ± 11 
500 mM 300 ± 3.9 110 ± 1.4 
 
 
 
 
Table 3.6.  Effect of buffer concentration on DNA capture with tube-mounted AOMs.  
Sample solutions contained 20 μg/mL -DNA. 
Concentration of 
Additional TE buffer 
Captured DNA (ng) % DNA Captured 
Blanks -7.2 ± 6.8 - 
0 mM 130 ± 56 34 ± 15 
10 mM -58 ± 78 -15 ± 21 
50 mM 32 ± 21 7.0 ± 4.6 
150 mM 14 ± 4.1 2.5 ± 0.7 
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Table 3.7.  Results of the initial test of the hybridization assay with oligonucleotide 
functionalized microspheres.   
Target beads for Sample  
Sample Concentration 
(ng/μL) S/N 
V. parvula Blank 0 48 ± 2.3 
V. parvula 
V. parvula  
PCR products 
22.52 89 ± 5.7 
P. melaninogenica 
P. melaninogenica  
PCR products 
13.30 280 ± 12 
C. gingivalis 
C. gingivalis  
PCR products 
29.11 9.7 ± 0.26 
 
 
 
Table 3.8.  Results of hybridization assays comparing four different blocking solutions.  
Assays were for V. parvula and the sample concentration was 17.32 ng/μL V. parvula 
PCR products.   
Blocking Solution Sample S/N 
Blank 58 ± 4.0 1% Blocker  
Casein in TBS 
PCR products 44 ± 7.4 
Blank 120 ± 20 
1% BSA in PBS 
PCR products 120 ± 38 
Blank 51 ± 5.4 
PBS SuperBlock 
PCR products 49 ± 13 
Blank 54 ± 3.8 
TBS Starting Block 
PCR products 51 ± 6.9 
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Figure 3.1.  An image of a tube-mounted AOM used to test DNA extraction efficiency.  
The bottom 2-3 mm is trimmed off of a 200 μL PCR tube and an AOM is hermetically 
sealed to the cut end.   
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Figure 3.2.  An image of the PCR chip (A) and a schematic of its cross-section (B).  
Pieces of PCR tubes are used to form reaction wells.  The schematic is not to scale.   
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Figure 3.3.  An image of the aluminum plate used to thermocycle the PCR chips (A) and 
a plot of the temperatures measured during thermocycling in a tube and on a chip (B).  
The plate has posts on the bottom that fit into holes in the thermal block of a commercial 
thermocycler.  The plate is shown inserted into the thermocycler with a PCR chip on top.  
The target PCR temperatures of 94 °C, 72 °C, and 56 °C are shown with dashed lines on 
the temperature plot.  
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Figure 3.4.  Schematic of the hybridization assay for detecting PCR products.  
Biotinylated PCR products hybridize to oligonucleotide probes on the microspheres and 
are detected with streptavidin-conjugated Alexa Fluor 488.   
 93
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Fluorescence images of an AOM before primer spotting (A), after primer 
spotting (B), and after washing with 25 μL of water (C).  The primers were covalently 
labeled with Alexa Flour 488 for visualization.  All of the images were taken with a 4 s 
exposure and the brightness and contrast settings are identical for all three images.   
 94
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.  Results of PCR of -DNA captured on a tube-mounted AOM.  For the 
reactions with DNA captured on tube-mounted AOMs, no additional DNA was added to 
the PCR solution.  The expected size of the PCR products for the -DNA primer set is 
294 bp.   
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Figure 3.7.  Results of PCR of -DNA captured on a tube-mounted AOM with pre-
spotted primers.  For the reactions using tube-mounted AOMs, no additional primers or 
DNA were added to the PCR solution.  The expected size of the PCR products for the -
DNA primer set is 294 bp. 
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Figure 3.8.  Images of two prototype PCR chips.  (A) has a reservoir with an ~100 μL 
volume, but these reservoirs had a tendency to leak.  (B) was made as a solid block of 
PDMS, eliminating leaking, but PCR was still not successful.   
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Figure 3.9.  Plot of the concentration of PCR products vs. the mass of AOM added to the 
reaction for 5 ng and 25 ng of template -DNA.  As the mass of AOM in the reaction 
mixture increases, the concentration of PCR products decreases.  An outlier is seen at 
0 mg AOM with 10 ng/μL PCR products.   
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Figure 3.10.  Plot of the concentration of PCR products vs. the concentration of Taq 
polymerase.  All solutions except the controls contained 4-5 mg of AOM, and 1% BSA 
was added to two solutions without adding additional Taq polymerase.  The addition of 
BSA or extra Taq polymerase resulted in an increased concentration of PCR products, but 
the addition of BSA resulted in a much more dramatic increase.   
 99
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.  Results of PCR comparing seven different blocking agents to prevent PCR 
inhibition from AOMs (A) and testing three of the best blocking agents with additional 
Taq polymerase (B).  For both A and B, all reactions except the controls contained 4-
5 mg of AOM.  While 1% BSA was the best blocking agent tested, it caused gelation of 
the PCR reagents.  Using 0.75% BSA with 5 units of Taq polymerase gave nearly the 
same concentration of PCR products as the control.  
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Figure 3.12.  Results of on-chip PCR of gDNA from S. pneumoniae and S. aureus.  The 
expected product size for the gyrB primers is ~300 bp.  The weak bands at ~60 bp were 
likely due to primer dimers.   
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Figure 3.13.  Results of on-chip PCR of gDNA from H. influenzae and S. salivarius.  
The expected product size for the gyrB primers is ~300 bp. 
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Figure 3.14.  Results of on-chip PCR of gDNA from S. mutans and S. mitis.  The 
expected product size for the gyrB primers is ~300 bp.  Only very weak product bands 
were seen for S. mutans and no product was seen from S. mitis.  Annealing temperature 
optimization could probably increase the product yields for both of these species, but 
since S. mutans and S. mitis are both control organisms, they were simply dropped from 
the group of target organisms.  The weak bands at ~60 bp were likely due to primer 
dimers.   
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Figure 3.15.  Results of on-chip nucleic acid extraction and PCR of gDNA from S. 
pneumoniae and S. aureus with primers pre-spotted into the reaction wells.  The expected 
product size for the gyrB primers is ~300 bp.  The bands at ~60 bp were likely due to 
primer dimers.   
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Figure 3.16.  Results of on-chip nucleic acid extraction and PCR of gDNA from H. 
influenzae and S. salivarius with primers pre-spotted into the reaction wells.  The 
expected product size for the gyrB primers is ~300 bp.  The first S. salivarius replicate 
contains only a very weak product band.  This is probably due to a bubble forming in that 
reaction well and preventing the reaction mixture from accurately thermocycling.  
Optimization is needed to increase the amount of product for H. influenzae.  The weak 
bands at ~60 bp were likely due to primer dimers. 
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Figure 3.17.  Results of PCR with multiplexed primers for control organisms.  All 
reactions contained primers for all four control organisms.  The last two lanes are the 
results from reactions that contained gDNA from both P. melaninogenica and V. parvula.  
The decrease in P. melaninogenica products from those reactions is due to competition 
with V. parvula.   
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CHAPTER 4 
MICROFLUIDIC CHIP FOR REAL-TIME PCR 
4.1 Introduction 
To fully integrate a PCR assay onto a POC device, the following steps are 
required: extraction of DNA from the sample, amplification via thermocycling, and 
amplicon detection.
1-5
  Chapter 3 described the development of a device integrating DNA 
extraction with PCR amplification, but the hybridization assay intended for amplicon 
detection proved unsuccessful.  Other analytical techniques like CE and electrochemical 
detection have been integrated with PCR on microfluidic devices for downstream 
detection of amplicons,
6-13
 but real-time PCR (rt-PCR) can perform amplification and 
detection simultaneously.  There are a number of detection strategies for rt-PCR, but all 
use a fluorescent reporter that causes an increase in fluorescent signal as the 
concentration of products grows.
14-17
  The first rt-PCR assay was described by Higuchi, et 
al., and used ethidium bromide (EtBr) to detect double stranded DNA.
18
  EtBr is an 
intercalating dye, so its fluorescence increases when it is inserted into double stranded 
DNA.  Since the amount of double stranded DNA in a PCR solution increases as the 
reaction proceeds, the fluorescent signal will increase and can be used to monitor the 
course of the reaction.   
Amplicon detection with an intercalating dye is very flexible since it can be used 
with any primer set, but it is not specific.
14, 19
  The dye will detect any double-stranded 
DNA in the reaction, even undesired non-specific amplification, which can lead to false 
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positives.
20, 21
  Due to the toxicity of EtBr, it has been replaced by another intercalating 
dye, SYBR Green.
14, 17, 21, 22
  An alternative to detection with an intercalating dye is to use 
a 5 nuclease assay, commonly called a TaqMan assay.  Holland, et al., described an 
assay using radioactively labeled oligonucleotide probes specific to the intended template 
that were degraded by the 5-3 exonuclease activity of the Taq polymerase.23  During 
amplification, the Taq polymerase cleaves 5 terminal nucleotides of double-stranded 
DNA, so if a probe is hybridized to the template strand, the polymerase will break it up 
into smaller pieces.
19, 21, 23-25
  If a fluorophore is attached to the 5 end of the probe and a 
quencher is attached to the 3 end, then the exonuclease will separate the fluorophore 
from the quencher resulting in an increase in signal.
14, 15, 25
  TaqMan probes are specific 
to the template DNA, so unlike with intercalating dyes, only amplification from the 
desired template will be detected.
14, 21, 24
  Other probe designs including Molecular 
Beacons, Scorpion primers, and Plexor primers have also been developed that are specific 
like the TaqMan probes but do not rely on the exonuclease activity of Taq polymerase.
14, 
19, 22, 24
   
In addition to integrating detection onto a POC microfluidic PCR device, it is also 
desirable to incorporate some degree of multiplexing to test for multiple organisms 
simultaneously.  The broad range primers used for multiplexing in Chapter 3 are not 
suitable for rt-PCR.  The product sizes of ~300 bp are longer than the ideal for rt-PCR 
which usually has products less than 200 bp long.
14, 26
  Multiplexing with the broad range 
primers could still be attempted with TaqMan or other sequence specific probes by 
putting different fluorescent dyes onto the probe for each organism, but the degree of 
multiplexing would be limited by the fluorophores.
15, 16, 25
  Due to spectral overlap, the 
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maximum number of fluorophores that can be simultaneously analyzed is approximately 
four.
27
  In addition to limitations in the degree of multiplexing, a single one-pot 
multiplexed assay can have problems with competition between primers and probes, 
overlapping primers producing dimers, and other non-specific interactions between 
primers and probes that can reduce amplification efficiencies.
28, 29
  An alternative to this 
is to make an array of reaction wells and use a different primer and probe set in each 
well.
30-33
  This multiplexing in space uses the same fluorophore for all of the reactions 
with the number of reaction wells limiting the degree of multiplexing.  Location is used 
to identify target organisms with fluorescence from a particular well denoting the 
presence of the target corresponding to the primer and probe set in that well.  
Multiplexing in space also simplifies the necessary optical detection instrumentation 
since only one filter set is needed.   
In this chapter, the 3-well PCR chip from Chapter 3 was adapted for real-time 
detection.  The three PCR tube reservoirs were replaced with a monolithic PDMS 
reservoir containing seven reaction wells.  The development of the rt-PCR assay and 
demonstration of successful extraction, amplification, and detection of DNA from lysed 
bacteria in saliva is described.  The real-time assay was designed using S. mutans, 
methicillin-susceptible S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) as 
model organisms.  
4.2 Materials and Methods 
Materials and Reagents 
Sylgard 184 PDMS was obtained from Dow Corning (Midland, MI) and prepared 
following the manufacturer’s recommendation with a 10:1 polymer to cross-linker ratio.  
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AOMs (13 mm diameter, 60 μm thickness, and 0.2 μm pores) were obtained from 
Whatman (Piscataway, NJ).  Brass blanks (brass alloy 360) were purchased from 
McMaster Carr (Chicago, IL).  Octyltrichlorosilane and DNase, RNase, and protease free 
water were purchased from Sigma Aldrich (St. Louis, MO).  ELIMINase cleaner was 
obtained from Decon Labs, Inc. (King of Prussia, PA).  Glass cover slips (20 mm x 
35 mm, 150 μm thick), Blocker BSA (10%) in PBS, and DNase and RNase free mineral 
oil were purchased from Thermo Fisher Scientific (Waltham, MA).  Platinum Taq DNA 
polymerase and 2x Platinum qPCR Supermix-UDG were purchased from Invitrogen 
(Carlsbad, CA).  Custom PrimeTime assay primers and double quenched probes were 
purchased from Integrated DNA Technologies (Coralville, IA).  Purified gDNA from S. 
mutans (ATCC 25175), MSSA (ATCC 25923), and MRSA (ATCC 700699) was 
purchased from ATCC (Manassas, VA).  Custom primer and probe sets and purified 
gDNA were resuspended following the instructions provided by their respective 
manufacturers.  Unless otherwise noted, all dilutions were performed using DNase, 
RNase, and protease free water.   
Cell lysate from MSSA cultures (ATCC 25923) was provided by Ryan Hayman 
from the Walt group at Tufts University.  The cultures were autoclaved to lyse the cells.  
The autoclaved cultures were stored at 4 °C, and the Walt group has successfully 
amplified DNA from similar lysate stored for more than 4 years under the same 
conditions (data not published).  Whole saliva was collected from a healthy volunteer by 
drooling into a clean centrifuge tube.  Samples were collected immediately prior to 
analysis and were discarded after the experiment.  A new sample was collected for each 
experiment using saliva.   
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Chip Design and Fabrication 
The microfluidic chip design consisted of three main parts: the wells used for 
sampling and PCR reactions, the AOM for DNA extraction, and the microfluidic channel 
and AOM support structure for fluid handling.  An image of the device and a schematic 
of its cross-section are shown in figure 4.1.  The design of the microfluidic base was 
identical to the 3-well chip described in Chapter 3.  A monolithic PDMS casting formed a 
reservoir containing seven wells, with each well measuring 2.4 mm in diameter and 
3.0 mm in height for a volume of ~13.5 μL. 
Molds for the 7-well PDMS reservoir were designed using BobCAD-CAM 
software (Clearwater, FL) and fabricated in brass blanks using a MicroMill DSLS 3000 
(MicroProto Systems, Chandler, AZ) computer numeric controlled (CNC) machine.  A 
double-sided molding strategy shown in figure 4.2 was used to cast a flexible PDMS 
mold (B) that mated with a second brass master (C).  The PDMS mold was pretreated 
with octyltrichlorosilane that acted as a mold release agent.  The PDMS mold and the 
second brass master were filled with uncured PDMS and degassed under vacuum, mated 
together to form the double-sided mold, and the PDMS was cured at 150 °C for 15 min.  
The resulting 7-well PDMS reservoirs (figure 4.2D) were then demolded.   
The microfluidic base of the chip was fabricated and bonded to a glass cover slip 
as described in Chapter 3.  An AOM was again placed over the micropost region of the 
chip.  A 7-well PDMS reservoir was cleaned with ELIMINase and dried with N2 gas, its 
underside was coated with a thin layer of uncured PDMS, and it was placed over the 
AOM.  The cover slip-PDMS-AOM-reservoir sandwich was heated to 95 °C for 15 min 
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to cure the PDMS and complete chip fabrication.  Chips were stored dry at room 
temperature.   
Instrument Set-Up and Detection 
Figure 4.3 shows an image of the instrument set-up for rt-PCR.  Fluorescence 
imaging was conducted using a modified AZ100 Multizoom microscope (Nikon 
Instruments Inc., Melville, NY) equipped with a Roper Scientific (Trenton, NJ) frame 
transfer camera (Model NTE/CCD-512-EBFT, GR-1).  A filter cube with 470/40 nm 
excitation, 495 nm dichroic, and 525/50 nm emission (Model 49002 ET – GFP, Chroma 
Technology Corp., Bellows Falls, VT) filters was used for fluorescence imaging of the 
FAM labeled probes.   
Thermocycling of the chip was performed using a 40 mm x 40 mm Peltier stage 
built in-house using a high temperature Peltier device (Model VT-127-1.4-1.15-71; TE 
Technology, Inc., Traverse City, MI) driven with a Wavelength Electronics, Inc. 
(Bozeman, MT) model MPT5000 controller.  A 250 μm thick layer of silver was bonded 
to the top of the Peltier device to ensure even heat distribution across its surface.  The 
bottom of the Peltier was mounted onto a custom temperature controlled heat sink held at 
60 °C by a recirculating water bath.  Custom software written in LabView (National 
Instruments, Austin, TX) using Automicromanager
34
 and Micromanager
35
 was used to 
coordinate fluorescence imaging with temperature cycling.   
PCR Development 
To use a chip, 10 μL of sample solution was added to each well and vacuum was 
applied to the waste reservoir until the entire sample had been pulled through the AOM, 
usually 5-10 min.  Then 5 μL of PCR master mix containing 1x Platinum qPCR 
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Supermix-UDG, 0.28 units of additional Platinum Taq DNA polymerase, and 1% BSA, 
as well as 0.5 μM of each primer and 0.25 μM of probe was added to each well.  Since no 
post-PCR analysis on-chip is needed with rt-PCR, gelation was not expected to be 
problematic and 1% BSA could be used instead of the 0.75% BSA used in Chapter 3.  
The PCR solution in the wells was overlaid with 5 μL of DNase/RNase free mineral oil, 
and a drop of uncured PDMS was placed in the waste reservoir to seal the channel and 
prevent evaporation during thermocycling.  The chip was then placed on the Peltier stage 
with a layer of mineral oil between the chip and the Peltier device to ensure good thermal 
contact.  The thermocycling program used for all experiments was 2 min at 50 °C, 2 min 
at 95 °C, 60 cycles of 30 s at 95 °C followed by 65 s at 66 °C, with a final extension step 
of 2 min at 66 °C.  No optimization of the PCR was performed.  Images were taken at the 
end of each amplification cycle with a 500 ms exposure time.  Chips were discarded after 
thermocycling, and a new chip was used for each experiment.   
Three bacterial targets were used as models for assay development: S. mutans, a 
control organism commonly found in the human mouth, MSSA, and MRSA.  Real-time 
primers and double quenched probes were designed using the PrimerQuest PCR design 
tool on the IDT website and sequences obtained from NCBI’s GenBank (accession 
numbers AE014133.1 for S. mutans and NC_002758.2 for S. aureus).  The primer and 
probes sequences were checked for specificity using NCBI’s Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast).  For S. mutans the primers target a 
137 bp region of the 16S rRNA gene that encodes for a subunit of the ribosomes that 
translate mRNA into proteins.  For S. aureus the primers target a 180 bp region of the nuc 
gene that encodes for an extracellular thermostable nuclease.  For MRSA the primers 
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target a 147 bp region of the mecA gene that encodes for an altered penicillin-binding 
protein (PBP-2a) that gives MRSA its antibiotic resistance.  The nuc primers will amplify 
template DNA from both MSSA and MRSA, while the mecA primers are specific to the 
gene that gives MRSA its antibiotic resistance.
36-38
  The primer and probe sequences are 
listed in table 4.1.   
Images were analyzed using ImageJ
39
 (National Institutes of Health, USA) and 
IgorPro (Wavemetrics, Lake Oswego, OR) to determine if successful amplification had 
occurred.  The average fluorescent signal from each well (~300 pixels) was measured in 
each image and plotted against cycle number.  An image taken 3-5 cycles before the start 
of amplification was used as the background and subtracted from all the other images.   
4.3 Results and Discussion 
Primer Testing and Sensitivity 
The primer and probe set for each model organism was first tested for specificity.  
These tests were done with a simplified chip design without the lower PDMS base layer 
containing the microposts and microfluidic channel.  AOMs and 7-well PDMS reservoirs 
were sealed directly onto glass cover slips with uncured PDMS.  The wells were filled 
with master mix containing primers and probes, and gDNA in solution.  The PCR 
solution was overlaid with mineral oil to prevent evaporation during thermocycling.  
Each primer and probe set was tested with purified gDNA from each of the three strains 
of bacteria and found to be specific to the species or strain for which it was designed.  
The rt-PCR results for the S. mutans primer and probe set against 1 ng of S. mutans 
gDNA and 1 ng of MSSA gDNA is shown in figure 4.4A.  An increase in fluorescence 
indicating amplification was seen only from the wells containing S. mutans gDNA and 
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not from the wells containing MSSA gDNA or from the blank well.  The test results for 
the S. aureus mecA primer and probe set with 1 pg of MRSA gDNA and 1 pg MSSA 
gDNA is shown in figure 4.4B.  Amplification is only seen from the wells containing 
MRSA gDNA and not from the wells containing MSSA gDNA or the blank well.   
A test of the limit of detection for the S. aureus nuc primer and probe set was also 
performed using a simplified chip.  Wells contained 1 ng (3105-4105 copies), 1 pg 
(300-400 copies), 30 fg (8-12 copies), or no (blank) MSSA gDNA.  The amplification 
plot is shown in figure 4.5.  A cycle threshold (Ct) line, designating a signal level above 
the background fluorescence, is indicated by the dashed line on the plot.  The cycle 
number when the fluorescence level crosses the Ct line (Ct value) is the cycle when 
amplification can first be detected and can be used to calculate the initial concentration of 
template in a reaction.
16, 20, 21, 25
  Duplicate reactions shown in the plot have nearly 
identical Ct values.  Amplification was seen in all wells containing template DNA, with 
amplification detected at earlier cycles for the wells containing greater amounts of DNA.  
Amplification was seen from as little as 8-12 copies of MSSA gDNA, which is thought to 
be sufficient for most clinical samples of interest such that further optimization was not 
deemed necessary.   
Cross-Contamination Between Wells 
In a diagnostic test, the sample (saliva from a patient) will be identical in all wells 
while the primer and probe sequences will vary.  In this way, simultaneous testing for 
many species and strains of bacteria by multiplexing in space is possible.  Since the same 
fluorophore is used for detection for all target sequences, it is critical that probes do not 
travel between wells, creating false positives.  There are three possible routes that primers 
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and probes could use to travel into other wells and cause cross-contamination.  The first 
is cross-contamination over the tops of the wells.  The volume of mineral oil overlaid on 
each reaction and the lack of fluid connecting the wells at their tops makes this unlikely.  
The second route is for cross-contamination at the interface between the wells and the 
membrane.  When the 7-well-reservoir is sealed to the AOM, uncured PDMS wicks into 
the pores of the AOM and is polymerized.  This effectively seals the wells at the surface 
of the AOM and prevents fluid from flowing laterally through the AOM.  Thus each well 
is fully isolated above the AOM.  The third route is for cross-contamination underneath 
the AOM in the micropost region.  Since the wells are not isolated from each other in this 
region, this is the most likely route of cross-contamination.   
To test this cross-contamination scenario, 1 pg of MSSA gDNA was captured in 
all seven wells of a chip.  This experiment also served to verify that the DNA capture 
described with the 3-well chip in chapter 3 would also be successful with this slightly 
altered chip design.  Master mix and primers and probes were added after DNA capture.  
S. aureus nuc primers and probes were added to three of the wells, S. aureus mecA 
primers and probes were added to another three wells, and the remaining well had no 
primers or probes added.  A diagram showing the identity of the primers and probes 
added to each well is shown in the upper left of figure 4.6A.  The primers and probes 
were added such that adjacent wells did not contain identical primers or probes.  The chip 
was then thermocycled.  Figure 4.6A shows the images collected after amplification 
cycles 25, 35, and 45 with increases in fluorescence only from the three wells containing 
S. aureus nuc primers and probes.  As shown in the amplification plot in figure 4.6B, the 
only wells showing amplification were those containing primers and probes for the S. 
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aureus nuc gene.  This indicates that each well remains isolated from the others to the 
extent that any amount of primers or probes traveling between the wells is not sufficient 
to result in an increase in fluorescence.  As future experiments were performed, no false 
positives were detected in any known negative wells.  This gives further confirmation 
that no cross-contamination is occurring between wells and that any increases in 
fluorescence from a well can be attributed to the primers and probes initially added to 
that well.   
Simultaneous Multi-Analyte Detection 
With no cross-contamination observed, the simultaneous detection of two 
bacterial species mixed in various combinations was undertaken.  The initial test sample 
solution contained gDNA from both MSSA and S. mutans with 1 pg of gDNA from each 
species captured in each well.  Primers and probes for the S. mutans 16S rRNA, S. aureus 
nuc, and S. aureus mecA genes were added to two wells each while the center well was 
left blank with no primers or probes.  Amplification was seen for the target S. mutans 16S 
rRNA and S. aureus nuc genes as shown in the amplification plot in figure 4.7A.  No 
amplification was seen in the blank and S. aureus mecA wells.  The results of the same 
experiment performed with a sample solution containing 1 pg of S. mutans gDNA and 
1 pg MRSA gDNA is shown in figure 4.7B.  Since both S. aureus nuc and S. aureus 
mecA primers will amplify DNA from MRSA, amplification was seen from all three 
primer sets.   
Test of Cell Lysate 
The next experiment used cell lysate as the sample to determine if the DNA 
extraction step would remove the PCR inhibitors present in real world samples.  Ten μL 
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of cell lysate from autoclaved MSSA cultures provided by the Walt group was used as 
the sample for each well of a chip.  Primers and probes for the S. aureus nuc gene were 
added to six of the wells and one well was left as a blank with no primers and probes.  
The amplification plot is shown in figure 4.8.  Amplification was seen from all wells 
except the blank, so DNA extraction with the AOM effectively removed any PCR 
inhibitors from the cell lysate.  The concentration of DNA in the cell lysate (or even the 
concentration of cells in the solution prior to autoclaving) was unknown.  Without a 
calibration curve, it is not possible to calculate the initial amount of DNA in the sample.  
Since the amplification can be detected at an earlier cycle than what is usually seen for 
1 pg samples of MSSA gDNA, the DNA was probably more concentrated than 
100 pg/mL, the concentration of the sample solutions used in the previous experiments.   
Detection of Bacteria in Saliva 
With the success of the cell lysate experiment, the detection of bacteria from a 
whole saliva sample was used to simulate a clinical sample.  Whole saliva sample was 
collected from a healthy volunteer and heated to 95 °C for 10-15 min to thermally lyse 
the cells.  On-chip DNA extraction was performed using the lysed sample.  Each of the 
three primer and probe sets (S. mutans 16S rRNA, S. aureus nuc, and S. aureus mecA) 
was added to two wells and the seventh well was left as a blank.  The amplification plot 
in figure 4.9 shows that only the S. mutans 16S rRNA wells exhibited amplification.  
S. mutans was chosen as a control organism because it is commonly found in the human 
mouth,
40
 so these results were as expected for a sample from a healthy individual.   
To simulate saliva from an infected individual, purified MSSA gDNA was spiked 
into saliva from the same healthy volunteer prior to thermal lysis.  The sample was spiked 
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with MSSA gDNA to a concentration of 10-12 copies/μL.  A volume of 10 μL of spiked 
saliva was added to each well and on-chip DNA extraction was performed.  The 
amplification plot is shown in figure 4.10A.  Amplification was seen for the S. mutans 
16S rRNA gene and S. aureus nuc gene while no amplification was seen from the S. 
aureus mecA and blank wells.  This experiment was repeated with MRSA gDNA in place 
of the MSSA gDNA.  The amplification plot is shown in figure 4.10B and, as expected, 
amplification was seen from all three primer and probe sets.  Differences between the 
three saliva experiments in the shape of the traces and in the apparent Ct value for the 
wells containing S. mutans 16S rRNA primers and probes are likely due to the initial 
amount of DNA in the sample.  The samples were collected on different days and at 
different times of day so variations in the concentration of a particular microorganism are 
to be expected.  For all of the experiments, the level of S. mutans present in the saliva 
sample was easily detected.   
4.4 Conclusions 
We have developed a microfluidic device that can extract DNA from lysed 
samples of whole saliva and perform rt-PCR amplification of the extracted DNA.  We 
have successfully used it to detect bacteria (S. mutans) and spiked pathogenic bacterial 
gDNA (from MSSA and MRSA) in a whole saliva sample.  The analysis time to go from 
saliva sample collection to results was less than 2.5 hrs.  As with the device in Chapter 3, 
the on-chip sample preparation is particularly fast and simple.  Though it only took a few 
minutes, the DNA extraction step still captured sufficient gDNA to detect 100-125 copies 
spiked into a whole saliva sample.  Again unchanged from the device in Chapter 3, the 
only actions the user must perform are pipetting reagents into the reaction wells and 
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applying vacuum to the waste reservoir.  Pairing the device with automated reagent 
dispensing could make it suitable for use in a clinical setting.  The use of rt-PCR to 
perform amplification and detection simultaneously was a timesaving improvement over 
the design in chapter 3 that required off-chip detection or a separate detection region on-
chip for hybridization assays.   
The majority of the analysis time (>2 hrs) was due to thermocycling.  While that 
is slow for a microfluidic chip, the overall analysis time for this device is still much faster 
than receiving results for samples sent to a centralized lab.  Slow thermocycling 
conditions were used to reduce any problems that could have been caused by poor 
thermal conductivity of the PDMS and glass substrates that make up the bulk of the chip.  
In addition, the chip is heated from below so that it can be imaged from above.  The PCR 
solutions are located above the AOM, so the entire bulk of the chip must be heated and 
cooled to the target temperature before the reaction mixture will reach the desired 
temperature.  Alternative and more efficient heating strategies, using more thermally 
conductive materials, and decreasing the volume of the wells would likely reduce the 
thermocycling time and allow more wells to fit on a chip, increasing the number of 
targets for which the sample can be simultaneously tested.  A commercial PCR assay, 
Cepheid’s GeneXpert system (Sunnyvale, CA), can test for a variety of targets in less 
than an hour, including sample preparation and thermocycling, but a different sample 
cartridge must be used for each target.  Our device can test for the presence of up to 
seven targets simultaneously.  Since many respiratory infections present with similar 
symptoms, testing for multiple organisms will save time.   
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For the development of the device, real-time data was collected, but it may not be 
needed for all applications.  In the developmental stages, collection of real-time data 
helps pinpoint experimental obstacles such as air bubbles or fluid evaporation.  
Monitoring the Ct values and the shape of the amplification curves also makes it easier to 
determine if experimental changes are inhibiting PCR.
41
  For a simple diagnostic device, 
end-point detection by measuring only the initial and final fluorescence of the reactions 
would be satisfactory for determining a positive or negative response.  This would 
simplify the data processing requirements of a reader device designed to operate the chip.  
For other applications, like the detection of oral microbes used as biomarkers for diseases 
such as pancreatic cancer, the concentration of the organism is important rather than just 
its presence.
42
  For those applications, quantitative real-time data would need to be 
collected.   
The pre-spotting of primers used for primer delivery with the 3-well chip in 
Chapter 3 was tested with this chip, but was not successful.  Those experiments and an 
alternative strategy to deliver different primer sets to each well prior to DNA extraction 
are discussed in Chapter 5.  The design of additional primer and probe sets would also be 
useful for this device. Because primers sets are not multiplexed in the wells, new primer 
and probe sets only need to be specific to the targeted organism and compatible with the 
thermocycling temperatures.  This also means that the primer and probe sets on a chip 
can be combined in any fashion and chips can be tailored to specific diseases or groups of 
symptoms.   
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4.5 Tables and Figures 
 
Table 4.1.  Primer and probe sequences for the target organisms and genes.  The probes 
are double-quenched and have a 6-FAM attached to the 5 end, an Iowa Black Dark 
Quencher FQ attached to the 3 end, and an internal ZEN quencher.   
Organism/gene Sequence 
S. mutans/16S rRNA 
forward 5-TCTTGATTGGACAGGTCAAGGAAA-3 
reverse 5-ACGGCCATTTGGTACATCAACCT-3 
probe 5-/6-FAM/AACCCGGTG/ZEN/CCAATGATGTTTGGGTT-
/IaBkQ/-3 
S. aureus/nuc 
forward 5-GGTGTAGAGAAATATGGYCCTGAAGC-3 
reverse 5-AGCCAAGCCTTGACGAACTAAAGC-3 
probe 5-/6-FAM/TGGACGTGG/ZEN/CTTAGCGTATATTTATGCT-
GA/IaBkQ/-3 
MRSA/mecA 
forward 5-CTGGAACTTGTTGAGCAGAGGTTCT-3 
reverse 5-ACTGCTATCCACCCTCAAACAGGT-3 
probe 5-/6-FAM/GACGTCATA/ZEN/TGAAGGTGTGCTTACAAGTG-
C/IaBkQ/-3 
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Figure 4.1.  An image of the 7-well rt-PCR chip (A) and a schematic of its cross-section 
(B).  The schematic is not to scale.   
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Figure 4.2.  Images of the molds used to make the 7-well PDMS reservoirs.  A brass 
master (A) is used to cast the PDMS half of the reservoir mold (B) which is mated to a 
second brass master (C) to form a double-sided mold used to cast the 7-well PDMS 
reservoirs (D).  The entire piece in B is 2.54 cm square.   
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Figure 4.3.  Image of the rt-PCR instrument set-up including the microscope, camera, 
and Peltier heater used for thermocycling the chip.  The custom heat sink built in-house is 
not shown.   
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Figure 4.5.  Real-time amplification plot for varying amounts of MSSA gDNA testing 
the limit of detection of the S. aureus nuc primer set.  1 ng of MSSA gDNA corresponds 
to 3105-4105 copies, 1 pg of MSSA gDNA corresponds to 300-400 copies, and 30 fg 
of MSSA gDNA corresponds to 8-12 copies.  A dashed Ct line is shown on the plot.  Ct 
value is a good indicator of starting concentration of template and duplicate reactions 
shown on this plot have nearly the same values.  Amplification is first detected at a later 
cycle for wells containing a smaller amount of template DNA.   
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Figure 4.8.  Real-time amplification plot for DNA extracted from MSSA cell lysate.  
Each well used 10 μL of MSSA cell lysate as the sample with six wells containing S. 
aureus nuc primers and probes and one blank well with no primers or probes.  Positive 
results are seen for all six S. aureus nuc wells, but not for the blank well.   
  135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9.  Real-time amplification plot for DNA extracted from whole saliva.  Each 
well used 10 μL of thermally lysed whole saliva as the sample while the primers were 
varied between the wells.  There are two wells corresponding to each of the three primer 
sets and one blank well without any primers or probes.  Positive results are seen only for 
S. mutans, the control organism.   
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CHAPTER 5 
PRIMER DELIVERY, RESTRICTION ENZYMES, AND FUTURE DIRECTIONS 
FOR THE PCR CHIP 
5.1 Introduction 
The PCR chip described in Chapter 4 integrates DNA extraction, amplification, 
and amplicon detection, and is easy to use, but the different primer and probe sets must 
still be pipetted into the individual wells following DNA extraction.  This step increases 
the potential for user error and the storage and dispensing of multiple solutions makes 
automation more complex.  Except for the specific primers and probes, all reagents are 
the same in each well; therefore, having preloaded primers and probes would simplify 
chip operation.  Primer delivery strategies to eliminate this extra pipetting step are 
described in this chapter.  The use of an intercalating dye (SYBR Green I) for amplicon 
detection instead of TaqMan probes and the resulting problems with non-specific 
amplification are also described.  The use of restriction enzymes to digest the gDNA 
before amplification to improve reproducibility and signal is also explored.   
Many strategies for PCR primer and reagent delivery have been described in the 
literature.  The simplest method is to dry the primers onto the surface of the reaction 
vessel.  Many microfluidic chips using dried primers have been described,
1-4
 and this 
strategy was used for primer delivery with the 3-well chip described in Chapter 3.  
Another approach is to cover or encapsulate the primers and other reagents in paraffin 
wax.
5-7
  The wax melts during the initial denaturing step of PCR, releasing reagents into 
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the solution.  An added benefit of using wax is that after the initial melting, it can form a 
layer on top of the reaction mixture to help prevent evaporation.  Primers have also been 
covalently coupled to microspheres, with PCR occurring at the surface of the bead.
8, 9
  
The Walt group has performed rolling-circle amplification, an isothermal technique, 
using oligonucleotides attached to microspheres through a biotin-streptavidin linkage that 
remains intact.
10
  We have also taken advantage of biotin-streptavidin binding to couple 
primers to microspheres and deliver them to the PCR reaction.
11
  For our microspheres, 
the streptavidin-biotin linkage remains intact during DNA extraction steps at room 
temperature but is broken during the initial heating steps of PCR, releasing the primers 
and probes into solution.
12
  These primer beads can be loaded into the wells of a PCR 
chip before DNA extraction and the primers will be released as amplification begins.   
Another possible improvement to the PCR assay is to incorporate restriction 
enzyme digestion prior to PCR.  PCR efficiency is usually better for smaller sized 
templates,
13
 and one way to reduce the size of template DNA in a controlled, 
reproducible manner is to use restriction enzymes.  These endonucleases recognize 
specific DNA sequences and then cleave both strands of double-stranded DNA into 
fragments.  Class I enzymes cleave the DNA at random sites unrelated to the recognition 
sequence.
14, 15
  Class II enzymes are much more useful since they cleave the DNA close 
to or within the recognition site, usually 4-8 bp long, and they are the most commonly 
utilized.
14, 15
  Class III enzymes also cleave the DNA at a specific site, but it is usually 
20-30 bp away from the recognition sequence.
14
  Two different enzymes may often 
recognize the same sequence (isoschizomers) but can sometimes cleave the DNA at 
different positions (neoschizomers).
14
  Class II enzymes are particularly useful for 
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applications like DNA mapping, to find the position of functional sites, and DNA 
fingerprinting, to identify species, strains, or even individuals from their gDNA.
14, 15
  
Less commonly, restriction enzymes are used to digest gDNA samples before PCR to 
improve amplicon yields and reduce non-specific amplification.
13, 16, 17
  Enzymes are 
chosen that will not cleave within the targeted sequence but will cleave peripheral regions 
that may non-specifically bind primers.
16, 17
  Pre-PCR digestion also makes circular 
bacterial gDNA linear, which can make the template DNA more available to the 
primers.
17
   
5.2 Materials and Methods 
Materials and Reagents 
Biotinylated forward and reverse primers for S. mutans 16S rRNA, S. aureus nuc, 
and S. aureus mecA with the sequences listed in table 4.1 were purchased from Integrated 
DNA Technologies (Coralville, IA).  ProMag 3 series streptavidin coated magnetic 
microspheres with a mean diameter of 3.28 μm were purchased from Bangs Laboratories, 
Inc. (Fishers, IN).  Tween 20 was purchased from Bio-Rad (Hercules, CA).  PCR tubes 
(200 μL) were obtained from Eppendorf (Hauppauge, NY).  Class II restriction enzymes 
MwoI, Bpu10I, and EcoRV-HF, and 10x NEBuffer 3 were purchased from New England 
BioLabs (Ipswich, MA).  Parafilm M was obtained from Bemis Company, Inc. (Neenah, 
WI).  Petri dishes, 10 mm x 15 mm, were obtained from BD Falcon (Franklin Lakes, NJ).  
Purified gDNA from S. mutans (ATCC 25175), MSSA (ATCC 25923), and MRSA 
(ATCC 700699) was purchased from ATCC (Manassas, VA).  Forward and reverse 
S. mutans 16S rRNA primers with AT-rich flaps, 10x PCR buffer, and 10,000x SYBR 
Green I nucleic acid gel stain were purchased from Invitrogen (Carlsbad, CA).  Primers 
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and purified gDNA were resuspended following the instructions provided by their 
respective manufacturers.  DNase, RNase, and protease free water water, DNase/RNase 
free polyurethane amplification tape (PCR tape), lithium chloride (LiCl), and Trizma 
base were purchased from Sigma-Aldrich (St. Louis, MO).  Tris Hydrochloride (Tris-
HCl) buffer, sodium chloride (NaCl), potassium chloride (KCl), and magnesium chloride 
(MgCl2) were purchased from Thermo Fisher Scientific (Waltham, MA).  TTL buffer 
was prepared with 100 mM Tris-HCl, 0.1% Tween 20, 1 M LiCl, and a pH of 8.0.  TT 
buffer was prepared with 250 mM Tris-HCl, 0.1% Tween 20, and a pH of 8.0.  Mock 
PCR buffer was prepared with 20 mM Trizma, 50 mM KCl, 2.5 mM MgCl2, and a pH of 
8.5.  Unless otherwise noted, all dilutions were made with DNase, RNase, and protease 
free water.   
Primer Beads 
Primer beads were made by coupling biotinylated primers to streptavidin coated 
magnetic microspheres.  The primer sequences are the same as the forward and reverse 
primer sequences listed in table 4.1, with the addition of a biotin attached to the 5 ends 
with a C6 spacer arm.  One set of beads was made for each primer set, with a 1:1 mixture 
of both forward and reverse primers coupled to the beads unless otherwise noted.  To 
couple primers to the beads, the beads were first washed and resuspended in TTL buffer.  
Biotinylated primers were diluted in TTL buffer and combined to make the 
oligonucleotide mixture with a concentration of 0.4 mM total primers, 0.2 mM each of 
the forward and reverse primers.  The oligonucleotide mixture was added to the beads in 
TTL buffer to make a solution with 2 nmol primers/mg beads and incubated for at least 
15 min at room temperature while shaking with a vortex mixer (Fisher Scientific, 
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Waltham, MA).  The beads were then washed twice with TT buffer and resuspended in 
mock PCR buffer for storage.   
Primer Delivery 
Primer delivery experiments were carried out using the 7-well rt-PCR chips 
described in Chapter 4.  DNA extraction and PCR were performed as described in section 
4.2 with the same thermocycling program, instrument set-up, and data analysis.  For 
experiments using spotted primers or primer beads, the primers and probes were omitted 
from the PCR master mix.  For primer spotting, the same primers and probes used in 
Chapter 4 were spotted into the wells prior to DNA extraction.  Tube-mounted AOMs 
were the same as those described in Chapter 3, and experiments with them were carried 
out as previously described.  For primer bead experiments, the TaqMan probes were not 
used.  Instead, 1x SYBR Green was added to the master mix for detection.  A 0.5 μL 
volume of primer beads, corresponding to approximately 500 nM delivered primers, was 
used in each reaction well instead of the primers and probes usually added with the 
master mix.   
Restriction Enzyme Digestions 
Restriction enzymes that cut close to the target region for each primer set but do 
not cut within any of the target regions were chosen using NEBcutter v2.0 on the New 
England BioLabs website.
18
  The restriction enzyme digestions were performed in PCR 
tubes and incubated using an Eppendorf Mastercycler personal (Eppendorf).  The 
digestions were performed in 10 or 20 μL volumes containing 1x NEBuffer 3, 
0.2 units/μL EcoRV-HF enzyme, 0.2 units/μL Bpu10I enzyme, and 1 pg/μL gDNA from 
each of type of gDNA in the sample.  The digestions were incubated at 37 °C for 30 min, 
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then MwoI enzyme was added to a concentration of 0.2 units/μL and the digestion was 
incubated at 60 °C for another 30 min.  One μL volumes of the digestion reactions were 
then used as samples for PCR.  PCR in tubes was performed with primer beads and the 
same PCR master mix used for on-chip PCR but with a 10 μL volume and without SYBR 
Green.  PCR products from PCR performed in tubes were analyzed with the Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA).  On-chip PCR with digested template was 
performed with primer beads, SYBR Green, and the same PCR master mix as usual.   
5.3 Results and Discussion 
Primer Spotting and On-Chip PCR 
After using the 7-well PCR chips to perform rt-PCR of gDNA captured on-chip 
with an AOM, the primer spotting technique described in Chapter 3 was tested with the 
real-time primer and probe sets.  Each well of a 7-well PCR chip was spotted with 
2.5 pmol of each primer and 1.25 pmol of probe from the S. aureus nuc primer and probe 
set and dried at room temperature.  PCR master mix and gDNA were then added to the 
wells, with 1 pg MSSA gDNA added to three wells, 1 pg MRSA gDNA added to three 
wells, and one well left as a blank, with water used in place of the gDNA solution.  DNA 
capture was not performed in this experiment.  The chip was thermocycled and the 
amplification plot is shown in figure 5.1.  Amplification was seen in all six positive wells, 
although it was detected later for one of the wells containing MSSA gDNA.  
Amplification is also detected in the blank well, possibly due to a small amount of 
template migrating into the blank well below the membrane.  While experiments in 
Chapter 4 demonstrated no detectable cross-contamination of primers and probes 
between wells, even a very small amount of template cross-contamination is much easier 
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to detect.  The chip was designed to use the same template in all wells, so a small amount 
of template cross contamination is not a concern with regard to future experiments.   
With this initial success, combining primer spotting and DNA capture with the 
real-time primers and probes was tested.  Each well of a chip was spotted with 2.5 pmol 
of each primer and 1.25 pmol of probe from the S. mutans 16S rRNA primer and probe 
set, and dried at room temperature.  Ten μL of solution containing 1 pg of S. mutans 
gDNA was filtered through six wells, and water was used in the seventh well (the blank).  
PCR master mix was then added to all wells and the chip was thermocycled.  No 
amplification was detected.  Since previous experiments described in Chapter 3 
combining pre-spotted primers with DNA extraction were successful, these results were 
surprising.  From this experiment, it was unclear whether the DNA capture step eluted the 
pre-spotted primers and probes or if the pre-spotted primers interfered with DNA capture.   
To determine the cause of PCR failure for pre-spotted primers combined with 
DNA extraction, primer spotting was tested using a 200 mM NaCl solution in place of the 
DNA solution.  Template DNA was added to the wells with the master mix.  S. aureus 
nuc primers and probes were spotted and dried into each well and 10 μL of the NaCl 
solution was filtered through the AOM in three wells to simulate the DNA capture step.  
The NaCl solution was used in place of water because the addition of NaCl was 
previously found to increase DNA capture and might increase primer retention if the 
primers were indeed being eluted.  The remaining four wells were used as positive 
controls, with pre-spotted primers but no NaCl wash or DNA capture step.  Master mix 
and 1 pg of MSSA gDNA was then added to all seven wells and the chip was 
thermocycled.  The amplification plot is shown in figure 5.2A.  While the positive 
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controls show amplification as expected, the wells incorporating a wash step do not.  This 
indicates that the primers and probes are eluted during DNA capture steps with this chip 
design.  Since primer spotting combined with DNA capture was previously successful 
with the 3-well chip, it is possible that the primers also remained on the AOM for this 
chip but that the probes did not.  To determine if successful amplification did occur, the 
PCR products from the experiment were analyzed with the Bioanalyzer.  The gel 
representation of the results is shown in figure 5.2B.  The expected product (180 bp) is 
seen for the four positive controls that did not incorporate a wash step, while a weak 
product band is seen for just one of the three wells that did use a wash step.  Though 
amplification occurred in that well, no product was seen from the other two wells, 
indicating that with these primer sets and chip design both primers and probes are eluted 
during DNA capture.   
To further investigate solutions for integrating primer preloading onto the 7-well 
chips, the previous experiment was repeated with tube-mounted AOMs.  The goal was to 
repeat the previous PCR failure and then use the tube-mounted AOMs to test out 
potential solutions.  After primer spotting and washing, the AOMs were punched out into 
clean PCR tubes, PCR reagents and gDNA were added, and PCR was performed on the 
bench top thermocycler with a 10 μL reaction volume rather than the 5 μL volume used 
on-chip.  Nine tube-mounted AOMs were spotted with primers and probes, and dried as 
before.  The amount of primers and probes spotted onto the AOMs was doubled since the 
reaction volume was doubled.  Three tube-mounted AOMs were positive controls that did 
not use a wash step.  Another three were washed with 10 μL of DNase/RNase free water, 
and the final three were washed with 10 μL of 200 mM NaCl.  For each set of three tube-
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mounted AOMs, two reactions were carried out with 1 pg MSSA gDNA and one was left 
as a blank.  The Bioanalyzer results are shown in figure 5.3.  The expected product band 
is seen for all tubes that contained gDNA, and no difference between those that 
incorporated a wash step and the positive controls was observed.  This experiment 
indicated that the tube-mounted AOMs did not correlate well to the chip and should not 
be used to explore ways to make primer spotting work on-chip.   
One possible reason for PCR failure in previous on-chip experiments was that the 
amount of primers, enough for a 1x primer and probe concentration in the final reaction 
volume, was too small.  Increased amounts of primers were spotted into the wells, from 
3x to 10x.  The experiment was performed with S. aureus nuc primers and probes, and 
with 1 pg MSSA gDNA used in all wells except the blank.  Two wells and the blank used 
3x primers and probes, another two wells used 4x primers and probes, and the final two 
wells used 10x primers and probes.  All wells were washed with 10 μL of DNase/RNase 
free water after the primers and probes were dried in the wells.  No amplification was 
seen for any amount of primers and probes.  Although it is not yet know why preloading 
of the primer sets worked for the 3-well chips with gyrB primers and the tube-mounted 
AOMs but doesn’t work for the 7-well chips and rt-PCR primer sets, it may be due to an 
increased surface area of AOM exposed in the 3-well chips and tube-mounted AOMs.  
With a larger surface area, the AOMs will have more sites for capturing oligonucleotides 
as well as gDNA.  It is also likely that longer template DNA is more strongly captured 
than short oligonucleotides, and the primers are eluted by the template during the DNA 
capture step.  With even 10x pre-spotted primers resulting in failed PCR, other primer 
delivery strategies were explored. 
 150 
Primer Beads and On-Chip PCR 
Primer beads, with oligonucleotides attached through a biotin-streptavidin 
linkage, are a different way to deliver the primers to each well before DNA extraction.  
The primers’ attachment to the microspheres prevents their removal, unlike pre-spotting 
directly onto the AOM.  The initial sets of beads were functionalized with either a 
forward or reverse primer.  Another set of beads was functionalized with an equal 
mixture of forward and reverse primers.  The first on-chip experiment with the primer 
beads was to determine if the primers would remain on the beads during DNA extraction.  
A mixture of primer beads with only the forward and reverse S. aureus nuc primers was 
added to three wells, primer beads with both S. aureus nuc primers were added to another 
three wells, and the final well was left as a blank with no primers.  Then 10 μL of 
100 pg/mL MSSA gDNA was filtered through each well, master mix containing SYBR 
Green was added and overlaid with mineral oil, and the chip was thermocycled.  The 
amplification plot is shown in figure 5.4.  Amplification was seen from all wells except 
the blank, showing that the primer beads retain the primers during DNA extraction and 
release them during the initial heating steps.  The primer concentration was sufficient for 
PCR and no inhibition due to the presence of the microspheres was observed.  Since 
beads with both primers worked just as well as a mixture of forward primer and reverse 
primer bead sets and required only one pipetting step to load onto the chip instead of two, 
beads with both primers were used for all future experiments.   
Storage of Primer Beads On-chip 
With successful primer delivery and PCR amplification using the primer beads 
demonstrated, the potential on-chip storage of the beads was explored.  For two chips, S. 
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aureus nuc primer beads were loaded into five of the seven wells.  One well was left 
empty to be used as a blank and another was left empty to use as a positive control with 
fresh primer beads loaded on the day of the experiment.  After primer bead loading, the 
reservoirs of the chips were covered with PCR tape, the chips were placed into Petri 
dishes sealed shut with Parafilm.  One chip was stored at 4 °C while the other chip was 
stored at room temperature.   
The chip stored at 4 °C was tested 39 days later.  Fresh primer beads, from a 
different batch than the beads stored on the chip, were loaded into the positive control 
well.  DNA extraction was performed with 1 pg of MSSA gDNA filtered through each 
well.  The chip was thermocycled, and the amplification plot is shown in figure 5.5.  All 
wells showed successful amplification although amplification is detected later for the 
fresh primer beads compared to those stored on-chip.  This could be due to some batch-
to-batch variation in the primer beads, or some unexpected inhibition of the PCR in the 
positive control well.  It was unknown whether the streptavidin-biotin linkage attaching 
the primers to the microspheres would remain intact for more than a month in solution, 
much less dried in the wells of a chip.  This experiment shows that the streptavidin-biotin 
linkage does remain intact during storage, retaining the primers on the beads, and 
preventing them from being eluted during DNA extraction.   
The chip stored at room temperature was tested 62 days after loading the primers.  
The same procedure used for the chip stored at 4 °C was used for this chip.  Primer beads 
from a different batch than the beads stored on-chip were again used for the positive 
control well.  The amplification plot is shown in figure 5.6.  The plot shows even better 
results for this chip than for the chip stored at 4 °C, which was unexpected since the 
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primer beads in solution are stored at 4°C.  The start of detectable amplification is closely 
grouped for the wells with stored beads, and only slightly later for the positive control 
with fresh beads.  This shows that the streptavidin-biotin linkage attaching the primers to 
the beads can remain intact for more than 2 months at room temperature without 
adversely affecting DNA extraction or PCR.  This is useful for a POC device, since the 
various sets of primer beads can be loaded into wells at the time of manufacture and the 
loaded chips can be stored by clinicians at room temperature until needed.   
Primer Dimers 
One potential problem with the primer beads is that they do not include a probe 
for product detection.  Instead, SYBR Green I intercalating dye is added into the master 
mix.  Unlike the TaqMan probes, intercalating dyes like SYBR Green are not specific to 
a particular sequence, detecting any double stranded DNA including non-specific 
amplification such as primer dimers.  Primer dimers are formed when the 3 ends of two 
primers anneal to each other with subsequent amplification by the polymerase.
19, 20
  The 
primer dimers not only compete with the intended target for PCR reagents, potentially 
inhibiting PCR, but also will be detected by intercalating dyes.
20, 21
  The presence of 
primer dimers is easily determined with gel electrophoresis.  Primer dimers will show up 
as a band approximately double the size of the primers.   
To determine whether primer dimers were forming during on-chip PCR with 
primer beads, a simple PCR chip, with a 7-well reservoir and AOM affixed directly onto 
a glass cover slip with PDMS, was loaded with S. aureus nuc primer beads in all wells.  
Master mix was then added to all wells, and 1 pg of MSSA gDNA was added to four of 
the wells while the remaining three were left as blanks.  The chip was thermocycled, and 
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the PCR products were collected off-chip and analyzed with the Bioanalyzer.  The 
amplification plot and Bioanalyzer results are shown in figure 5.7.  In the plot, all wells 
show amplification, including the blanks.  The false positives are explained by the 
Bioanalyzer results, which show primer dimer formation in nearly all of the wells.  Even 
in lanes 3 and 4, which correspond to the traces showing the earliest detectable 
amplification, there are very weak primer dimer bands.  One of the other wells with 
template DNA shows bands for both products and primer dimers (lane 1), while the final 
MSSA gDNA well shows only primer dimers and no product (lane 6).  Primer dimer 
bands are also seen for all of the blank wells.  As the amplification plot demonstrates, 
with these experimental parameters it is impossible to tell desired amplification from 
undesired, non-specific amplification without further analysis.  This could lead to false 
positives for a POC device relying on rt-PCR detection with SYBR Green. 
The products from the on-chip storage of primer beads could not be analyzed with 
the Bioanalyzer, so there is no way to know whether the amplification detected was of the 
target DNA or of the primers.  However, whether the products were from the target or 
from primer dimers, the amplification results do indicate that the primers are retained on-
chip through storage and subsequent DNA extraction.  
Following the detection of primer dimers from PCR with primer beads, a variety 
of strategies were tested to reduce or eliminate their formation.  The first attempt was to 
add primer flaps to the PCR primers.  Primer flaps were described by Afonina et al. and 
are AT-rich 12-bp regions (AATAAATCATAA) added to the 5 end of both the forward 
and reverse primers.
22
  They were found to increase signal intensity during PCR for 
reactions with probes or SYBR Green, and in some cases, improve PCR performance and 
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Ct values.  These flaps were added to the S. mutans 16S rRNA primers and tested with a 
simple chip and the same experimental conditions used for the previous experiment but 
with S. mutans gDNA instead of MSSA gDNA.  Since this was an initial test and 
biotinylated primers are significantly more expensive, these primers were not coupled to 
beads but instead were added to the master mix for a final concentration of 500 nM of 
each primer.  The amplification plot and Bioanalyzer results are shown in figure 5.8.  No 
primer dimers were seen in three of the wells with gDNA, although the fourth well with 
gDNA (lane 6) showed no product band and only a very weak primer dimer band.  The 
primer dimer bands were also very weak for the blanks, but were easily detectable with 
the SYBR Green in the amplification plot.  One blank was also a false positive, with a 
product band but no primer dimer band (lane 5).  The source of contamination for that 
well is unknown, but it was not a problem in future experiments.  While the primer flaps 
did reduce primer dimer formation, they did not eliminate it sufficiently enough to 
reliably distinguish positive and negative results for unknown samples.   
The next avenue explored for primer dimer elimination was to increase the 
annealing temperature.  Increased annealing temperatures lead to decreased PCR 
efficiency but increased specificity.
23
  Annealing temperature optimization for the primer 
sets was first performed in PCR tubes with an Applied Biosystems Veriti 96 Well 
Thermal Cycler (Applied Biosystems, Foster City, CA).  The reactions were performed 
with the same 5 μL volume and reagent concentrations used on-chip.  Four sets of 
reactions were carried out: S. aureus nuc primer beads with MSSA gDNA, S. aureus 
mecA beads with MRSA gDNA, S. mutans 16S rRNA beads with S. mutans gDNA, and S. 
mutans 16S rRNA primers with flaps with S. mutans gDNA.  For each primer/template 
 155 
combination, the annealing temperature was varied from 64 °C to 74 °C in increments of 
2 °C.  At each annealing temperature there was one blank reaction and one positive 
control containing 1 pg template DNA.  The PCR products were analyzed on the 
Bioanalyzer following thermocycling.  The Bioanalyzer results for S. aureus nuc/MSSA 
and S. mutans 16S rRNA with flaps/S. mutans are shown in figure 5.9.  For S. aureus nuc 
primer beads (figure 5.9A), primer dimers form with a 64 °C annealing temperature, but 
not at higher annealing temperatures.  At 72 °C and above, amplification of the target 
fails.  For this primer set an annealing temperature of 66-70 °C is optimal to reduce 
primer dimer formation.  For S. aureus mecA beads, primer dimers are only seen at 64 °C 
while amplification of the target fails at 70 °C and above, giving an annealing 
temperature range of 66-68 °C.  For S. mutans 16S rRNA beads, amplification fails at 66 
°C, but primer dimers still form at both 64 and 66 °C.  No useful annealing temperature 
range was found for the S. mutans 16S rRNA beads.  The results were more unusual for 
the S. mutans 16s rRNA primers with flaps (figure 5.9B).  Amplification fails at 70 °C 
and above, but primer dimers formed at every annealing temperature tested.  This 
suggests that the primer flaps are unsuited for the S. mutans 16S rRNA primer sequences.  
The addition of the primer flaps may result in the 3 end of one of the primers forming a 
complex more stable than usual primer dimers, or impurities remaining from the 
synthesis of a longer oligonucleotide facilitated the formation of primer dimers.   
The annealing temperature optimization experiments indicated that for S. aureus 
nuc and mecA primer beads, increasing the annealing temperature to at least 66 °C should 
eliminate primer dimers.  Since the current annealing temperature used on-chip is 66 °C, 
there may be a difference between the solution temperature and Peltier stage temperature.  
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A 68 °C annealing temperature was tested with the S. aureus nuc primer beads, MSSA 
gDNA, and a simple chip.  Three wells contained 1 pg MSSA gDNA as the sample, three 
wells were blanks without template DNA but still contained primer beads, and the final 
well was a blank without template or primers.  After thermocycling, the PCR products 
were analyzed for primer dimers with the Bioanalyzer.  The amplification plot and 
Bioanalyzer results are shown in figure 5.10.  The amplification plot shows what appears 
to be amplification in the blank wells containing primer beads, especially compared to the 
blank well without primers.  Unfortunately, noise was a problem for this experiment, 
which was later found to be due to fluctuations in the intensity of the Nikon Intensilight 
(Nikon Instruments Inc., Melville, NY) used with the microscope.  The Bioanalyzer 
results confirm the conclusions drawn from the amplification plot, with primer dimers in 
most of the blank wells and two of the wells with template DNA, including one positive 
control well with failed amplification of the target sequence (lane 5).  Since S. aureus nuc 
was the primer set most tolerant of higher annealing temperatures, these results indicate 
that raising the annealing temperature may not eliminate primer dimers on-chip.  The 
annealing temperature cannot be raised further without making both of the other primer 
sets incompatible with the thermocycling program and preventing them from being used 
on the same chip as the S. aureus nuc primers.   
Another strategy to reduce primer dimer formation is to reduce the concentration 
of primers in solution.  This was tested with the S. aureus nuc primer beads, MSSA 
gDNA, and a simple chip.  Four wells contained 1 pg MSSA gDNA as the sample and 
three wells were blanks without template.  All wells contained half the amount of primer 
beads used in previous experiments.  No amplification was detected from any of the 
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wells.  While this strategy eliminated primer dimer formation, it also eliminated product 
formation.  An alternative strategy to either reduce primer dimers or change how the 
products are detected will need to found for the primer beads to eliminate the potential 
for false positives with a chip used in a clinical setting.   
Template Digestion with Restriction Enzymes 
Performing a restriction enzyme digestion of the template DNA before PCR can 
improve PCR efficiency.  Three enzymes that will cut the template DNA within a few 
base pairs of the target sequences were tested for compatibility with PCR by performing 
amplification of digested template in a tube-based reaction.  Separate digestions of 
template gDNA for each of the three targets were performed with a 1 pg/μL 
concentration of gDNA.  One μL of digested DNA was then used as template for PCR in 
tubes.  For each target there were four blanks (two without template and two without 
primers), four positive controls with undigested template, and four reactions with 
digested template.  The MSSA gDNA was paired with S. aureus nuc primer beads, the 
MRSA gDNA was paired with S. aureus mecA beads, and the S. mutans gDNA was 
paired with S. mutans 16S rRNA beads.  An annealing temperature of 68 °C was used to 
prevent primer dimer formation.  The concentration of PCR products from each reaction 
was determined with the Bioanalyzer.  The average product concentration for each 
template/primer set pair with undigested and digested template is listed in table 5.1.  
When the standard deviations are taken into consideration, there is no significant 
difference between the results for undigested and digested template for MSSA and 
MRSA.  For S. mutans, no amplification was detected for the undigested template.  This 
was likely due to the higher annealing temperature.  That product was detected for 
 158 
digested S. mutans template indicates that enzyme digestion does not inhibit PCR and 
may improve annealing.   
PCR with digested template was then tested on-chip with MRSA gDNA, S. 
aureus mecA primer beads, and a simple chip.  The digestion was performed off-chip as 
previously described.  Three reaction wells contained digested template gDNA, three 
wells contained undigested template gDNA (positive controls), and the final well was a 
blank containing primers but no template.  The usual annealing temperature of 66 °C was 
used.  The amplification plot and Bioanalyzer results are shown in figure 5.11.  Bubbles 
were a problem for one of the wells with digested template and that trace has been 
removed from the amplification plot, but the Bioanalyzer results for that well are shown.  
Amplification was successful for all wells with digested or undigested DNA.  The 
Bioanalyzer results confirm amplification of the target region, although the product bands 
are weaker for two of the wells with digested DNA and one of the positive controls.  For 
this experiment, the concentration of products measured by the Bioanalyzer may be lower 
than the concentration that was present on-chip.  The amount of solution collected from 
each well was small, and there was more gelation from BSA than had been seen in 
previous experiments.  Those factors made it difficult to prevent mineral oil from making 
up part of the 1 μL samples used with the Bioanalyzer.  The Bioanalyzer results also 
show that primer dimers were not a problem for most wells, including the blank, in this 
experiment, although that may be due to experimental variation or underestimation of 
product concentrations rather than the enzyme digestion.  These results do show that 
restriction digestion of the template DNA does not inhibit PCR, although the 
improvement in the results was modest with this chip design.   
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5.4 Conclusions and Future Directions 
We have developed a primer delivery method for the microfluidic rt-PCR device 
that is compatible with DNA extraction with AOMs.  Primers spotted directly onto the 
AOM, as in Chapter 3, were washed off during the DNA extraction step.  Instead, 
biotinylated primers were coupled to streptavidin-coated microspheres that were added 
into the reaction wells.  The beads are too large to travel through the pores of the AOM, 
and the streptavidin-biotin linkage firmly anchors the primers during DNA extraction.  
The initial heating steps of PCR break the streptavidin-biotin linkage, releasing the 
primers.  The primer beads were successfully used to perform on-chip PCR with DNA 
extraction.  Further experiments found they could be stored on-chip for at least 39 days at 
4 °C or 62 days at room temperature and still be used for PCR.   
Only primers were coupled to the microspheres, so SYBR Green was used for 
product detection instead of the fluorescently labeled probes used in Chapter 4.  One 
disadvantage of SYBR Green is that it does not detect specific sequences, so it will detect 
unintended amplification products such as primer dimers.  Bioanalyzer analysis of 
products from PCR with primer beads found that primer dimers were a recurring problem 
with these experimental conditions.  The addition of AT-rich primer flaps to the S. 
mutans 16S rRNA primers was tested to eliminate primer dimers, but was ultimately 
unsuccessful.  The annealing temperature was also optimized for each primer set.  Higher 
annealing temperatures appeared to be beneficial for the S. aureus nuc and mecA primer 
sets in tubes, but were unsuccessful on-chip.  Reducing the concentration of primers in 
the reaction was tested, but was also unsuccessful on-chip under the current experimental 
parameters.   
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Primer dimers can cause false positives when used with non-specific intercalating 
dyes, so a means to eliminate them or a more specific detection strategy must be found.  
One possibility is to couple the probes to the beads along with the primers.  Although 
biotinylated dual-quenched probes have not been previously described and the probes 
already have a fluorescent dye on one end and a quencher on the other, it may still be 
possible to biotinylate them either internally or as a second modification to one end.  
SYBR Green was used for detection at first rather than adding an untested probe 
modification as an additional unknown variable into the experiments.  Another possibility 
is to continue using SYBR Green for detection, but perform a melting curve analysis after 
the completion of PCR.  In a melting curve analysis, the temperature of the solution is 
gradually increased from 50 °C to 95 °C.  As the double stranded DNA denatures, the 
fluorescence signal from SYBR Green decreases greatly.  A plot of the derivative of the 
fluorescence with respect to temperature (dF/dT) vs. temperature will show peaks at the 
melting temperatures for any DNA present.
24
  Primer dimers have a lower melting 
temperature than longer PCR products, so the presence of primer dimers or specific 
amplification can be determined.  Melting curve analysis was attempted using our set-up, 
but the noise from the Intensilight was too great to determine a sharp melting 
temperature.  New light sources are currently being investigated, so this may be a 
possibility in the future.  Current work in the Ramsey group suggests that reducing the 
reaction volume may also reduce primer dimer formation as the total number of 
molecules is reduced (results not published).  Work to design and fabricate chips with 
much smaller reaction volumes is ongoing.   
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We have also found three restriction enzymes that are compatible with the target 
sequences for which our primers were designed.  The digested gDNA could be 
successfully amplified both in tubes and on-chip without PCR inhibition.  For S. mutans 
gDNA in tubes, the digested template was amplified even when the annealing 
temperature was too high for the undigested template.  A further use for the digested 
DNA could be to use the primer beads for specific DNA extraction from samples, 
eliminating the need for DNA extraction with the AOM and providing a means of 
selective sample concentration.  Since the enzymes were selected to cut near one end of 
the target sequence, the digested DNA may be able to hybridize to the primers on the 
beads.  A mixture of beads for a pool of targets could be incubated with digested template 
DNA and then the beads with hybridized template could be loaded into individual 
reaction wells with a greatly decreased reaction volume.  A general master mix could 
then be added, and thermocycling could begin.  The beads would need to be encoded in 
some way, similar to the antibody-functionalized microspheres from Chapter 2, so that 
the results from each bead could be attributed to the appropriate target.  If the reaction 
wells are small enough for reactions with single primer beads, an array large enough for 
digital PCR may be possible, and the amount of template might be quantified directly, 
without using Ct values and a calibration curve.
2, 25, 26
   
Another potential improvement would be to include a reference dye for 
normalization of the fluorescent signal.  This could simplify data analysis and eliminate 
the need to subtract an image from a few cycles before amplification to account for well-
to-well variations in the baseline fluorescent signal.  Developing a reader instrument for 
the chip, particularly one that includes automated reagent loading, would make it more 
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user friendly.  If the chip requires the user to pipette reagents into each well, even if the 
same volume of the same solution is used for all wells, there is greater potential for user 
error.  Automation of all chip operation after saliva sample introduction would be ideal.  
Finally, primer sets for additional organisms with annealing temperatures compatible 
with the three sets currently in use, and potentially with the three restriction enzymes, 
would expand the usefulness of the device.  Multiple, non-biotinylated primer sets for H. 
influenzae, S. pneumoniae, and S. salivarius were designed, but they either had problems 
with primer dimer formation or annealing temperatures disparate from those used for the 
S. aureus and S. mutans primer sets.  If an alternative approach is found with reduced 
primer dimer formation (such as using lower reaction volumes), some of those primer 
sets could be retested.   
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5.5 Tables and Figures 
 
Table 5.1.  Average concentration of products from PCR with undigested and digested 
template for three template and primer set combinations.  No products were detected 
from PCR with undigested S. mutans gDNA.   
Concentration of PCR products (ng/μL) 
Template/primer set 
Undigested template Digested template 
MSSA/S. aureus nuc 4.11 ± 0.32 3.52 ± 0.42 
MRSA/S. aureus mecA 2.07 ± 0.32 1.81 ± 0.08 
S. mutans/S. mutans 16S rRNA - 0.36 ± 0.14 
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Figure 5.1.  Real-time amplification plot for MSSA and MRSA gDNA with S. aureus 
nuc primers and probes pre-spotted into the wells.  DNA extraction with the AOM was 
not performed.  Positive results are seen for all wells containing template DNA.  Possible 
amplification in the blank well indicates that it may have become contaminated with a 
small amount of template.   
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Figure 5.3.  Results of PCR of MSSA gDNA with S. aureus nuc primers pre-spotted onto 
tube-mounted AOMs.  Primers and probes were spotted onto all of the tube-mounted 
AOMs.  The first set of three were used as positive controls without a wash step, the 
second set of three were washed with DNase/RNase free water, and the third set were 
washed with 200 mM NaCl.  Amplification was seen from all reactions containing 
gDNA, whether or not a wash step was performed.   
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Figure 5.4.  Real-time amplification plot of the S. aureus nuc gene using primer beads.  
A mixture of primer beads for the forward and reverse primers were added to three wells, 
primer beads with both primers were added to another three wells, and the final well was 
a blank with no primer beads.  Each well contained 1 pg MSSA gDNA as the sample.  
Template DNA was extracted onto the AOM after adding the primer beads into the wells.  
Amplification is seen from all wells with primers, demonstrating that the primers are 
retained on the beads through the DNA extraction step.   
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Figure 5.5.  Real-time amplification plot with S. aureus nuc primer beads stored on-chip 
for 39 days at 4 °C.  Primer beads were loaded into five wells of a chip before storing it 
for 39 days.  On the day PCR was performed, fresh primer beads, from a new batch, were 
added to a sixth well.  The final well was left as a blank.  Each well contained 1 pg 
MSSA gDNA, extracted onto the AOM, as the sample.  Amplification was seen from all 
wells containing primers, so the primer beads can be stored on-chip for at least 39 days at 
4 °C and still be used for PCR.   
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Figure 5.6.  Real-time amplification plot with S. aureus nuc primer beads stored on-chip 
for 62 days at room temperature.  Primer beads were loaded into five wells of a chip 
before storing it for 62 days.  On the day PCR was performed, fresh primer beads, from a 
new batch, were added to a sixth well.  The final well was left as a blank.  Each well 
contained 1 pg MSSA gDNA, extracted onto the AOM, as the sample.  Amplification 
was seen from all wells containing primers, indicating that the primer beads can be stored 
on-chip for at least 62 days at room temperature and still be used for PCR.   
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Figure 5.9.  Results of annealing temperature optimization for S. aureus nuc primer 
beads (A) and S. mutans 16S rRNA primers with flaps (B).  The annealing temperature 
was varied from 64-74 °C with a blank and positive control (PC) with 1 pg of MSSA (A) 
or S. mutans (B) gDNA at each temperature.  Primer dimers form at every temperature 
for S. mutans primers with flaps, but 66-70 °C eliminated them for the nuc primer beads.   
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